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GLUTATHIONE S-TRANSFERASE P IN GLUCOSE HOMEOSTASIS IN MICE 
Shubha Ghosh Dastidar 
November 11, 2016 
High calorie diets have fostered the current pandemic of obesity and comorbid 
conditions of non-alcoholic fatty liver disease (NAFLD), systemic insulin 
resistance (IR) and type 2 diabetes (T2D). Hepatic glutathione S-transferases 
(GSTs) are dysregulated in obesity, NAFLD and diabetes. The multifunctional 
GST pi isoform (GSTP) catalyzes acrolein metabolism and inhibits JNK (c-Jun 
NH2-terminal kinase). The purpose of this study was to test specifically whether 
GSTP deficiency disturbs glucose homeostasis in mice. Hepatic GST proteins 
were downregulated by short-term high fat diet (HFD) in wild type (WT) mice 
concomitant with glucose intolerance, increased hepatic JNK activation and 
protein-acrolein adducts. To address whether GSTP contributes specifically to 
HFD-induced sequelae, metabolic phenotype of GSTP-null mice was assessed. 
Body composition, fasted levels of blood glucose and insulin were similar in WT 
and GSTP-null mice. However, the study revealed that GSTP-null mice were 
glucose intolerant. GSTP-null mice were glucose intolerant. Furthermore, this 
defect in glucose homeostasis was due not to peripheral IR but to an impaired 
capacity to increase plasma insulin level in response to hyperglycemia. In 
exploring the effect of insufficient insulin release, the pyruvate tolerance test 
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(PTT) revealed greater PTT AUC in GSTP-null mice, indicating enhanced hepatic 
glucose output. Glucose intolerance was positively correlated with the level of 
pyruvate intolerance. However, no differences were found in fasting mRNA levels 
of the gluconeogenic enzymes: phosphoenolpyruvate carboxykinase (Pepck) and 
glucose-6-phosphatase (G6pc) between WT and GSTP-null livers. Treatment of 
GSTP-null mice with the JNK inhibitor, SP600125, attenuated hepatic 
gluconeogenesis compared with vehicle-treated littermate controls. Collectively, 
these data illustrate a novel role of GSTP in glucose handling via JNK regulation 
and hepatic gluconeogenesis – a heretofore unrecognized function. Thus, future 
studies are warranted for studying how GSTP dysregulation influences the 
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Disease Statistics of the West: An Emerging Epidemic 
 
The incidence and prevalence of obesity, T2D and liver disease have soared 
dramatically in the Western world over the past two decades with the current 
rates of adult and pediatric obesity reported to be an estimated 20–30% of the 
US population [1] [2-4]. According to NHANES reports, more than one-third 
(34.9% or 78.6 million) of U.S. adults are obese and 68% are overweight or 
obese [5]. Obesity is a major driver of the T2D epidemic, hepato-biliary and 
gallbladder diseases, cardiovascular pathologies, neurodegenerative disorders, 
asthma, and a variety of cancers [6]. In addition, obesity is often accompanied by 
hepatic steatosis, which is part of the spectrum of NAFLD, currently the most 
common liver disorder in the US [2]. A strong association between NAFLD and 
T2D has been demonstrated: more than 90% of obese patients with T2D have 
NAFLD [7]. In addition, around 20% of patients with NAFLD progress to non-
alcoholic steatohepatitis (NASH), liver cirrhosis and failure [8, 9].  
 




Once considered a disease of the West, T2D and NAFLD are an escalating 
epidemic in South Asia and in the Western Pacific Region [10-12]. The 
International Diabetes Federation has predicted that the number of individuals 
with diabetes will increase from 240 million in 2007 to 380 million in 2025, with 
more than 60% of them belonging to Asia, because it remains the world's most 
populous region.  
A multitude of interrelated factors have fostered the diabetes pandemic, 
including rapid industrialization and urbanization and the ensuing lifestyle 
changes [10, 13]. The effect of the intrauterine environment and the resulting 
epigenetic changes may also underlie increased risk of T2D and other chronic 
diseases in adult life [14, 15]. Epigenetic changes being transmittable to future 
generations become intergenerational. Impaired fasting glucose (IFG) and 
impaired glucose tolerance (IGT) are high-risk conditions for diabetes and 
cardiovascular disease [16]. China and other countries in Western Pacific Region 
have a high prevalence of IGT [17].  
 
‘Diabetes: A Disease of Paradoxes’ 
 
Several lines of evidence support that obesity promotes clusters of risk factors 
that potentiate IR and, obese individuals experience substantially elevated 
comorbidities. However, not all obese individuals develop cardiometabolic 
abnormalities, thus presenting the paradox of the “metabolically healthy obese” 
or “insulin sensitive obese” subjects who are protected against complications of 
T2D [18, 19]. Such individuals do not exhibit increased oxidative stress in 
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visceral adipose tissue and maintain increased levels of antioxidant enzymes. In 
contrast, NAFLD and/or T2D are reported in an estimated 60% of the young, lean 
urban population in Asian communities [10, 20, 21]. Taken together, the 
dynamics of the diabetes epidemic pose the conundrum that not all obese 
progress to diabetes and not all diabetics are obese, implicating genetic and/or 
environmental factors as likely determinants governing interindividual 
susceptibility.  
 
Overarching Research Goals 
 
Diabetes and its complications are preventable and highly treatable. A 
randomized trial in China demonstrated that dietary and exercise intervention 
reduced diabetes risk by 31% to 46% in individuals with IGT (reviewed in [10] 
and references therein). In observational studies and randomized trials 
conducted in Asia and Europe, control of multiple risk factors reduced cardiorenal 
complications and all-cause mortality by 50% to 70% in individuals with T2D [10]. 
Therefore, a better understanding of the pathophysiology of T2D holds great 
promise. In particular, investigations focused on the differences between obese 
insulin sensitive, obese insulin resistant and lean diabetic subjects or animal 
models that recapitulate these attributes of the human disease can delineate key 
factors that either contribute to or prevent the development of IR. 
 




Elevated blood glucose levels take the center stage in the definition of diabetes 
mellitus. The word Diabetes stems from the Greek root meaning to siphon, to 
represent the frequent urination observed in patients, while the term mellitus has 
its origins in the Latin word for honey, referring to the sweet taste of urine in 
these patients. The nomenclature incorporates the diverse pathophysiologic 
events resulting in the characteristic hyperglycemia. Type 1 diabetes is an 
autoimmune disease resulting in the death of pancreatic β cells and usually 
manifests early in life. It is associated with symptoms such as frequent urination, 
weight loss, and increased plasma levels of ketone bodies and little or no 
circulating insulin. Type 1 diabetes account for 10% of the total diabetic 
population of the United States. In contrast, T2D results from IR, defined as the 
lack of responsiveness to insulin in peripheral tissues such as muscle, fat and 
liver.  
Diabetes is diagnosed clinically by elevated fasting plasma glucose over 
126 mg/dL where the normal range in humans is 70-110 mg/dL [22]. 
Alternatively, an oral glucose tolerance test can detect T2D as elevated plasma 
glucose over 200 mg/dL two hours after administering a 75 g glucose load [23]. A 
longer term marker of blood glucose levels is glycated hemoglobin A1c (HbA1c), 
which normally accounts for approximately 5% of circulating hemoglobin and in 
diabetic patients is found at 7% or greater abundance. The metabolic 
derangements underlying T2D include decreased insulin-stimulated glucose 
uptake in fat and muscle, increased hepatic glucose production and impaired 
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pancreatic β cell function as determined by insulin secretion (Berne, R.M. and 
M.N. Levy, Physiology. 3rd ed. 1993, St. Louis: Mosby Year Book xiv, 1071).  
Interrogating the natural progression of T2D in humans requires 
elucidation of the relationship between plasma glucose and insulin levels in 
relation to insulin resistance and secretion. A stepwise increase in plasma 
glucose occurs during progressive glucose intolerance with a corresponding 
increase in plasma insulin response. Subjects with IGT are able to mount an 
elevated insulin secretory response and prevent development of hyperglycemia. 
Due to obesity, inactivity, aging and genetic factors, IR increases. Pancreatic 
beta cells respond to IR by increasing insulin secretion in the normal 
physiological state to maintain normoglycemia. In susceptible individuals β cell 
function begins to decline. This decline of β cell function -- in the face of usually 
severe but stable IR -- leads to first postprandial hyperglycemia and then fasting 
hyperglycemia. Most individuals can maintain a high degree of compensatory 
insulin secretion throughout their life to prevent development of T2D. The failure 
of adequate beta cell compensation underlies the onset of frank T2D. The 
proportion of individuals (obese or otherwise) that is unable to adequately 
compensate become diabetic.  
For patient therapy, guidelines target maintaining FPG levels within the 
normal range of 70-110 mg/dL dL (5-7 mM) or glycated hemoglobin A1c below 
7%. To counter the deleterious effects of hyperglycemia, therapeutic 
interventions for T2D are aimed at decreasing glucose production in the liver or 




Oxidative Stress, Lipid peroxidation and Aldehydes  
 
Obesity is a state of chronic oxidative stress and inflammation, key determinants 
of the causal progression to diabetes and liver disease [24]. Oxidative stress is 
defined as a significant imbalance between antioxidant defenses and pro-
oxidative reactive oxygen species (ROS) in favor of the latter, resulting in (often) 
cellular dysfunction. Substantial evidence implicates ROS as key perpetrators of 
metabolic dysfunction [25]. ROS, such as hydroxyl radicals, are highly reactive 
and cause direct oxidative modification of proteins, lipids, carbohydrates and 
DNA. Membrane lipids are extremely susceptible to free radical-mediated injury. 
ROS initiates peroxidation of polyunsaturated acyl chains of membrane 
phospholipids to result in Hock cleavage and subsequent formation of lipid-
derived reactive aldehydes of various chain lengths such as trans-4-hydroxy-2-
nonenal (4-HNE), trans-4-oxo-2-nonenal (4-ONE), acrolein, malondialdehyde, 
glyoxal, crotonaldehyde, and 2-hexenal [26]. Even transient increases in ROS 
levels lead to accrual of lipid peroxidation products. Aldehydes are highly reactive 
and covalently modify cysteine, histidine or lysine residues of proteins in a 
process generically referred to as protein carbonylation with deleterious 
consequences for protein function and stability. For example, 4-HNE and acrolein 
modification of proteins can inhibit their activity and cause protein degradation 
[27-29]. Consistent with the view that ROS-mediated injury can be attributed in 
part to lipid-derived aldehydes, almost 7% of AFABP in adipose tissue was 
covalently modified by 4-HNE in obese insulin-resistant C57Bl/6J mice, resulting 
in a decreased binding affinity for fatty acids [30]. Increased plasma protein 
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carbonyls, as a biomarker of systemic oxidative stress, was positively correlated 
with IR in obese patients [31] and was significantly decreased following treatment 
[32, 33]. As a result of these (and many more) findings, there has been a surge in 
interest in evaluating how aldehyde metabolism and protein carbonylation may 
serve as a mechanistic link between oxidative stress and IR. Investigating the 
mechanisms and consequences of oxidative stress in insulin-responsive tissues 




The capability of cells to counter oxidative stress is primarily mediated through 
antioxidant response elements (AREs), which are largely under the control of the 
transcription factor nuclear factor E2-related factor 2 (Nrf2) which, under pro-
oxidative conditions, induces expression of phase I and II metabolizing enzymes 
and transporters pivotal to cellular detoxification [34, 35]. Glutathione S-
transferases (GSTs) are a multigene multifunctional family of dimeric phase II 
detoxification enzymes that catalyze the conjugation of reduced GSH to reactive 
endogenous and exogenous electrophiles [36]. GSTs can be found in the 
cytosol, mitochondria, and microsomal membranes of most tissues throughout 
the body [36]. Based on their amino acid sequence and substrate specificity, 
eight classes of GSTs (namely GST alpha, mu, pi, theta, sigma, zeta, kappa and 
omega) have been identified in mammals. Although less than 10% of the primary 
sequence is conserved, all GST isozymes have a similar topology and two 
domains responsible for protein folding. The N-terminal domain (residues 1–80) 
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comprises one third of the protein and forms the G-site. It is composed of four β-
sheets with three flanking α-helices, a structural motif common to thioredoxin, 
and other proteins that have evolved to bind GSH or cysteine [37]. This region 
contains a catalytic tyrosine, serine, or cysteine residue that directly interacts with 
the thiol group of GSH [37]. Distinct from their capacity to mediate cellular 
detoxification, several GSTs have been ascribed additional cellular functions 
such as cell signaling, as molecular carriers (‘ligandins’) [38], peroxidase enzyme 
activity and modulation of calcium channels and ryanodine receptors [39]. In 
keeping with their critical role as cellular “caretaker” proteins, metabolic 
syndrome is associated with altered GST expression and function in liver and 
adipose tissue. Studies of GSTs during progression of obesity, diabetes and 
NAFLD in humans and animal models have reported both increased and 
decreased GST expression in vivo as described in the following sections. The 
impact of NAFLD on GST expression and activity appears to be isoform and, 
possibly, species specific as reviewed in detail by Merrell and Cherrington [40].  
 
Obesity, Diabetes and Glutathione S-transferases 
 
Similar to NAFLD, the effects of obesity and diabetes on hepatic GST expression 
and activity are inconclusive. An increase in hepatic GST activity was reported in 
streptozotocin-induced diabetic mice, but not in spontaneously (db/db and ob/ob) 
or alloxan-induced diabetic mice [41, 42]. In contrast, Thomas et al. (1989) 
reported that hepatic GST activity was decreased in diabetic rats and restored by 
insulin administration [43]. The reason for this discrepancy remains unknown but 
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may be due, in part, to the use of primarily nonselective GST enzymatic activities 
as indirect indicators of GST expression. Kim et al. demonstrated that insulin and 
glucagon regulate, in an opposing manner, the expression of alpha-class GSTs 
and that glucagon completely inhibits pi class GST expression in primary cultured 
rat hepatocytes, suggesting that hepatic GST expression may be decreased 
during diabetes [44]. GSTA4 is downregulated specifically in adipose tissue of 
obese, insulin-resistant humans and murine models, and also in 3T3-L1 
adipocytes treated with tumor necrosis factor (TNF)-α [30, 45, 46]. Mitochondria 
from both GSTA4-silenced 3T3-L1 adipocytes and adipose tissue of GSTA4-null 
or obese C57BL/6J mice accumulate ROS and exhibit compromised respiration, 
resulting in impaired glucose and lipid homeostasis. This suggests that TNF-α–
induced downregulation of GSTA4 is a major determinant linking inflammation 
with oxidative stress and IR [45]. Boden et al. performed a detailed analysis of 
subcutaneous fat biopsies from six lean and six obese nondiabetic subjects and 
observed an upregulation of GSTP along with ER stress-related unfolded protein 
response (UPR) proteins such as calreticulin, protein disulfide-isomerase A3 by 
proteomic analysis [47]. The authors also confirmed by western blot, an 
upregulation of several UPR stress-related proteins, including calnexin and 
phospho-JNK-1, a downstream effector of ER stress. Furthermore, RT-PCR 
analysis revealed upregulation of the spliced form of X-box-binding protein-1, a 
potent transcription factor and part of the proximal ER stress sensor inositol-
requiring enzyme-1 pathway, demonstrating evidence of ER stress-activation of 
JNK as a possible link between obesity, IR, and inflammation in human subjects. 
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Grant et al. reported perturbations in GSTs in examining global gene expression 
profiles of adipose tissue in dogs during the transition from a lean to obese 
phenotype [48]. The authors fed high fat diet to female beagles and collected 
subcutaneous adipose tissue biopsies, blood, and DEXA measurements at 0, 4, 
8, 12, and 24 weeks of feeding. They found that, among other genes, GSTP was 
induced at all time points, while GSTM4, GSTT2 and GSTO1 showed increased 
expression at 4 and 8 weeks, which then decreased to baseline levels or lower at 
12 and 24 weeks. Interestingly, the highest food intake occurred at 4 and 8 
weeks which led the authors to conclude that the induction of GSTM4, GSTT2 
and GSTO1 may be due to metabolic stress associated with adipose tissue 
expansion and lipid storage. In contrast, some reports have also documented a 
decrease in GSTs during obesity and attributed it to increased oxidative stress. 
Kirpich et al. reported a decrease in hepatic GSTP and GSTM protein in high-fat 
lard diet-fed C57Bl/6J mice [49]. In a separate study, investigators fed male 
Wistar rats a cafeteria diet, described as a fat-rich hyper caloric diet containing 
pate, chips, chocolate, bacon, biscuits, and chow in a proportion of 2:1:1:1:1:1 
(65% calories from fat), for 65 days and examined the expression of over 12,500 
transcripts in epididymal adipose by DNA microarray [50]. Redox and stress 
proteins were among the pathways down-regulated in obese animals with a 2.6-
3.2 fold downregulation of GSTP transcript. Miller et al. determined effects of 
dietary composition on obesity in mice by feeding either a high-carbohydrate diet 
(HC; 10% fat energy) or a high-fat energy–restricted diet (HFR; 60% fat energy) 
for 18 weeks. Further, to identify obesity-associated genes with persistently 
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altered expression following weight reduction, mice were fed either a standard 
low-fat diet (LF; 10% fat energy), an unrestricted high-fat diet (HF; 60% fat 
energy), or a HF diet followed by weight reduction (WR) [51]. Microarray analysis 
identified global differences in adipocyte gene expression patterns with 
downregulation in several GSTs. In conclusion, specific GST isozymes appears 
to be dysregulated with metabolic disease progression.  
 
Glutathione S-transferase P 
 
The GST Pi isoform (GSTP) has been ascribed diverse catalytic and non-
catalytic functions relevant to metabolic disease [36]. GSTP catalyzes the 
Michael addition of acrolein to glutathione with high specificity as a substrate to 
facilitate its detoxification [52]. GSTP is overexpressed in many human tumors, 
and is a well-documented cancer biomarker [[53] and references therein]. In 
humans, the dimeric GSTP is the most abundant GST isozyme in most tissues, 
although it is reported to be absent from hepatocytes with its expression in liver 
restricted to a few specialized cell types, including biliary epithelial and Ito cells 
[54]. Despite this, it is clearly a major hepatic protein as it produces abundant 
discernible spots on Coomassie blue-stained 2-DE gels of normal human liver  
[55]. Expression of GSTP in hepatocytes has been shown to increase in certain 
liver pathologies, such as alcoholic liver disease [54]. In contrast, in mice, GSTP1 
is the most abundant of the GST isoforms in normal liver [36]. In addition, a 
second GSTP isoform (GSTP2) is expressed as a product of a distinct gene 
located in tandem with GSTP1 on chromosome 19. A GSTP1/2 knockout mouse 
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model was created to study the function of GSTP in vivo. GSTP-deficient (GSTP-
null) did not show any obvious phenotype, although some null mice had higher 
body weights than controls [56]. Studies using GSTP-null mice have elucidated 
GSTP to be an important metabolic determinant of 7,12-dimethylbenz 
anthracene (DMBA)-induced carcinogenesis [56], APAP-induced hepatotoxicity 
[57], allergic airways disease [58], tobacco-induced endothelial dysfunction [59], 
cyclophosphamide-induced urinary bladder and cardio-toxicity [60] and more 
recently myocardial sensitivity to ischemia-reperfusion injury [61, 62]. GSTP was 
also found to be a major GST isoform in the heart, lung and aorta and 
contributed significantly to total GST conjugating activity in those tissues.  The 
relative abundance of GSTP protein in other major tissues germane to obesity 
and diabetes, such as skeletal muscle, adipose tissue depots and pancreas has 
not been examined.   
 
Regulation of GSTP Expression  
 
The following section encompasses in brief the current understanding of each 
regulatory mechanism of GSTP, with emphasis on the known and anticipated 
contribution to obesity and diabetes. GSTP expression may be regulated by any 
(or a combination) of the following mechanisms: Transcription factors (Nrf2), 
epigenetics, microRNA, and hormonal, all of which are affected by metabolic 





GSTP gene expression is highly inducible and regulated at the transcriptional 
level by the activation of nuclear factors that sense electrophilic stressors of 
different origin and bind specific sequences of GST promoter region, such as the 
antioxidant responsive element (ARE). Nuclear factor erythroid 2-related factor 
(Nrf2) is one of the most well-characterized transcription factors recognized to 
stimulate the induction of GSTP as well as of other cytosolic GSTs and phase II 
genes (reviewed in [63]). Nrf2 is activated by electrophiles through the Keap1-
Nrf2 pathway. In normal liver cells, Keap1, a cytoplasmic effector, binds to Nrf2 in 
the cytoplasm, causing the rapid degradation of the latter in the cytoplasm. This 
releases the interaction of Nrf2-Keap1 and promotes nuclear accumulation of 




The human GSTP promoter region contains a TATA box, two SP1 sites, an 
insulin response element, and an antioxidant response element within an AP1 
site [64]. The relative influence of hormones versus oxidative stress during 
diabetes may be critical for regulation of GSTP expression and activity. It is 
interesting to note that glucagon and insulin were shown to modulate GSTP 
expression in isolated rat hepatocytes [44]. The addition of insulin increased 
alpha-class GST protein levels, whereas alpha- and pi-class GST protein levels 
were markedly decreased in hepatocytes cultured with glucagon. In contrast, mu-
class GST protein expression was unaffected by insulin or glucagon treatment. 
This study demonstrated that insulin and glucagon regulate, in an opposing 
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manner, the expression of alpha-class GSTs and that glucagon completely 
inhibits pi class GST expression in vitro, suggesting that hepatic GST expression 
may be decreased during diabetes. Relationships between antioxidant enzymes 
and insulin are not unprecedented. However, these effects were measured in 
vitro and may be unrelated to the in vivo physiologic perturbations or be 
insufficient to cause them, making simple associations in humans difficult. 
Nonetheless, it is interesting to consider that altered pancreatic hormone levels in 
insulin resistant states such as diabetes and NAFLD in humans can affect 
hepatic GSTP (and other GSTs) protein expression or activity.  
GSTP1 promoter contains an insulin response element motif [65]. The 
insulin response element (IRE) in a gene promoter contains a T(A/G)TTT motif 
essential for insulin inhibition of transcription. Insulin-mediated suppression of 
hepatic GSTP through this IRE motif in diabetes via an as yet unidentified 
transcription factor is an attractive notion. In addition to conferring insulin 
inhibition, the IRE is required for maximal glucocorticoid stimulation. IRE 
sequence, location, and function are conserved among the human, rat and 
mouse IGFBP-1 promoters, further underscoring the importance of this element. 
Interestingly, the gluconeogenic enzyme, PEPCK also contains the IRE motif. 
Insulin inhibits and glucocorticoids stimulate hepatic expression of PEPCK and 
tyrosine aminotransferase (TAT). IREs mapped to the PEPCK and TAT gene 
promoters resemble the human and rat IGFBP-1 IREs by requiring the same 
T(G/A)TTT motif for maximal insulin inhibition and glucocorticoid stimulation of 
promoter activity. This suggests that the same protein(s) binds the T(G/A)TTT 
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sequence to confer insulin and glucocorticoid responsiveness to these genes. 
Identifying such novel transcription factor(s) (and co-activators, co-repressors) 
may reveal if insulin and glucocorticoids regulate hepatic expression of proteins 
such as GSTP, PEPCK (and many more) in vivo. Collectively, these observations 
illustrate the complex interwoven mechanisms of regulation of pancreatic 
hormones, gluconeogenic enzymes and hepatic GSTs that remain to be 




GSTP is frequently inactivated by acquired somatic CpG island promoter 
hypermethylation in multiple cancer subtypes including prostate, breast, liver, 
and blood cancers [66]. Epigenetically-mediated GSTP1 silencing is associated 
with decreased cellular detoxification capability. Epigenetic modification of GSTP 




Recent studies suggest that microRNAs may regulate GSTP expression. miR-
133b reduced GSTP1 expression by 2.1 fold in prostate cancer cells [67]. miR-
513a-3p sensitized human A549 lung adenocarcinoma cells to chemotherapy by 
targeting GSTP1 [68]. miR-133a repressed the expression of GSTP1 at mRNA 
and protein levels [69]. Similar findings were observed in human bladder cancer 
[70] and lung squamous cell carcinoma [71]. Because diet-induced obesity and 
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diabetes is associated with dysregulation of microRNAs, regulation of hepatic 
GSTP abundance by microRNAs following HFD is plausible.  
Interleukin-6 
GSTP1 has recently been shown to be an IL-6 target gene [72]. Inhibition of 
GSTP1 activity by an IL-6 or IL-6 receptor mAb correlated with increased 
platinum (and paclitaxel) sensitivity in renal cancer cells [73]. Plasma IL-6 is 
elevated in obesity and is a well-known mediator of inflammation-induced insulin 
resistance and hepatic gluconeogenesis via JNK pathway. [74, 75]. Therefore, it 
will be interesting to consider the possibility of a relationship between IL-6 and 
GSTP in vivo in obese states.  
GST Polymorphisms and Diabetes 
 
T2D is a multifactorial disease that is influenced by environmental risk factors, 
lifestyle habits and genetic susceptibility. Human GSTs are polymorphic, and 
genetic variations and deletion genotypes of GSTs are relatively prevalent in 
human populations. GSTP1 maps to chromosome 11q13 [76], a locus linked to 
the development of diabetes [77, 78]. Four haplotypes of GSTP that differ 
structurally and functionally owing to variation in two residues have been 
determined and characterized, as follows: GSTP haplotype A (WT), with Ile105 
and Ala114; haplotype B, with Val-105 and Ala-114; haplotype C, with Val-105 
and Val-114; and haplotype D, with Ile-105 and Val-114. The presence of valine 
at position 105, which is part of the H-site, was shown to disrupt the water 
hydrogen-bonding network, thereby allowing GSTP to accommodate less bulky 
substrates [79]. Polymorphic forms of human GSTP1 differ in their ability to 
17 
 
metabolize acrolein [80]. The I105V variant has a reduced ability to conjugate 
electrophilic species with reduced glutathione, leading to lower enzyme activity 
towards normal GSTP substrates and may therefore sensitize cells to free 
radical–mediated toxicity. While the presence of valine at position 114 does not 
affect the standard GSTP activity, the V105/V114 haplotype is a more potent 
inhibitor of JNK activity than the wildtype haplotype (I105/A114) [81]. Thus, 
interindividual susceptibility to oxidative stress may well be contingent upon 
population differences in GSTP expression and function. However, interpretation 
of GST polymorphism studies is subject to the caveat that GSTs are inducible 
enzymes.  Induction of one GST could offset the contribution of the other GST-
null or polymorphic allele, as illustrated by the increased expression of GSTP in 
individuals lacking GSTM (a common polymorphism in Caucasians), presumably 
as a compensatory defense mechanism against carcinogens [82]. Nonetheless, 
recent studies in diverse population groups have reported significant association 
of both the GSTM1 and GSTT1 null genotypes with the risk of developing T2D 
[83-93]. Two reports studying North Indian and Egyptian subjects respectively 
were the only ones demonstrating a significant association of the GSTP SNP 
(A313G) with T2D [83, 94]. Although these correlative results remain nascent, 
the principle that genetic variation may play a role in diabetes susceptibility takes 
on a greater relevance in light of the connections between GSTP and protein 
carbonylation, and S-glutathionylation and JNK kinase regulation, processes 
pivotal to glucose homeostasis. Therefore, well-designed animal studies are 
needed to delineate a causal and tissue-specific contribution of GSTs to 
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diabetes. In this regard, GSTP-null mice are an important model to probe GSTP-
specific roles under controlled conditions that are not affected by the variables 
that confound epidemiologic studies.  
GSTP and Acrolein Detoxification 
 
Although GSTP catalyzes conjugation of glutathione with different electrophilic 
substrates, the enzyme has particularly high affinity for small unsaturated 
aldehydes, such as acrolein [20, 52, 95]. Acrolein is an unsaturated aldehyde 
that readily reacts with cellular nucleophiles such as glutathione and cysteine and 
histidine side chains of proteins. Acrolein toxicity could be attributed to the high 
reactivity of the α,β–unsaturated structure of the aldehyde, because addition of 
nucleophiles such as glutathione to the site of unsaturation attenuates acrolein 
reactivity and toxicity. Although acrolein reacts spontaneously with glutathione, 
this reaction is catalyzed by GSTP increasing the rate (600-fold) of conjugation of 
acrolein with GSH [52]. Thus, enzymatic conjugation by GSTP facilitates and 
enhances the detoxification and removal of acrolein and other related aldehydes 
[52]. The physiological relevance of this metabolic proclivity is supported by 
studies in rodents that demonstrate a role for GSTP in protection against 
cardiovascular toxicity of direct acrolein exposure and acrolein-containing 
tobacco smoke as well as cyclophosphamide-induced urotoxicity and 
cardiotoxicity, and myocardial ischemia/reperfusion injury [59-62] . Among all the 
αβ-unsaturated aldehydes, acrolein is by far the strongest electrophile and reacts 
100-fold more rapidly with thiols than 4-HNE [96, 97]. Humans are exposed to 
acrolein per oral (food and water), respiratory (cigarette smoke, automobile 
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exhaust, and biocide use) and dermal routes, in addition to endogenous 
generation (metabolism and lipid peroxidation). Acrolein has been implicated in 
several disease states, including spinal cord injury, multiple sclerosis, 
Alzheimer’s disease, cardiovascular disease, diabetes mellitus, and neuro-, 
hepato-, and nephro-toxicity. At the cellular level, acrolein exposure has diverse 
toxic effects, including DNA and protein adduction, oxidative stress, 
mitochondrial disruption, membrane damage, endoplasmic reticulum stress, and 
immune dysfunction [reviewed in [98]]. Much has been elucidated and written 
about the contribution of acrolein and protein-acrolein adducts in disease 
development/ progression [reviewed in [98, 99]]. However, free acrolein in 
tissues is highly volatile and reactive, which renders accurate detection and 
quantification of endogenous acrolein challenging. The existing methods require 
complicated approaches using carbonyl derivatizing reagents, as elucidated with 
murine hearts [61]. Alternatively, as an index of acrolein toxicity, protein acrolein 
adducts are estimated in plasma and tissues by immunological analyses such as 
Western blotting and dot blotting. Accordingly, dietary obesity in mice was 
associated with increased tissue and plasma levels of protein–acrolein adduct 
[100]. Acrolein-insulin adducts was shown to reduce both its hypoglycemic 
effects in rats and glucose uptake in 3T3-L1 adipocytes. Also, urinary acrolein 
correlated with glycated hemoglobin HbA1c in type-2 diabetic individuals [101]. 
Although reports documenting the involvement of acrolein toxicity in diabetes are 
sparse and a definitive role is not currently discernable, in light of the pathological 
importance of acrolein, alterations in acrolein metabolism and detoxification due 
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to GSTP dysregulation in obesity and diabetes may have important 
consequences. 
 
GSTP in Cell Signaling: JNK Activation and Protein S-glutathionylation 
 
Distinct from its role in detoxification, GSTP has also been ascribed further roles 
in a variety of cellular functions such as in regulation of stress-induced cell-
signaling. Through protein-protein interactions via its C-terminus, GSTP can 
sequester c-jun N-terminal kinase (JNK) and act as a negative regulator of this 
stress kinase [102]. Oxidative stress can destabilize the GSTP-JNK complex 
leading to an activation of downstream targets of JNK. Embryonic fibroblasts 
from GSTP-null mice exhibited JNK activation and a higher basal JNK activity 
compared with those from wild type mice [102]. The interaction between GSTP 
and JNK was also demonstrated in cell lines using apoptosis as an indicator of 
JNK activation. Accordingly, the protection of dopaminergic neurons against 
dopamine-induced apoptosis was attributed to an increase in the expression of 
GSTP and the subsequent suppression of JNK activity [103]. Conversely 
apoptosis was shown to increase in a human leukemia Jurkat cell line following 
etoposide treatment, which was ascribed to the dimerization of GSTP resulting in 
the release of JNK from the GSTP-JNK complex and thus increased JNK activity 
[104].  
GSTP content is high in normal male mouse liver (∼500 μg/g) [105], which 
results it being in excess of the Kd for the GSTP-JNK association [106]. Thus, 
JNK might be expected to be totally inactive in vivo. The observation of 
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constitutive JNK activity in wild type liver is attributed to the fact that under basal 
conditions cellular GSTP content consists of both monomers and homodimers of 
which only the former binds JNK [102]. Accordingly, GSTP-null mice exhibit 
constitutive JNK activity and expression of specific phase II detoxification 
enzymes and antioxidant proteins that are downstream JNK targets [107]. Thus, 
GSTP serves as a sensor of intracellular changes in redox potential and has the 
capacity to regulate kinase pathways. Pharmacologically, this interaction served 
as the basis for development of the anti-cancer GSTP inhibitor, Ezatiostat 
hydrochloride (Telintra) [108].  
In addition, GSTP catalyzes the forward protein S-glutathionylation 
reaction (i.e. the addition of GSH), a reversible post-translational modification 
that alters protein conformation and charge to impact function and/or subcellular 
localization [53]. Selective modification can affect proteins including, enzymes, 
receptors, structural proteins, transcription factors and transport proteins and 
may also alter a variety of protein-protein interactions. For example, 
glutathionylation of activated aldose reductase in ischemic mouse heart was 
demonstrated to be mediated by GSTP [109]. Furthermore, GSTP is itself 
susceptible to S-glutathionylation. Most approaches lack the sensitivity to identify 
the proteins and pathways regulated by S-glutathionylation under basal 
conditions in whole organisms. McGarry et al reported the quantification and 
identification of S-glutathionylated target proteins from murine liver, using a 
highly sensitive methodology combining high-accuracy proteomics with tandem 
mass tagging [110]. Significant enrichment of S-glutathionylated mitochondrial 
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and Krebs cycle proteins suggests an involvement of this modification in energy 
metabolism processes in vivo. However, little overall difference between the 
hepatic protein S-glutathionylation profiles between wild-type and GSTP-null 
mice was demonstrated [111]. The authors concluded that whereas GSTP may 
be an important determinant of protein S-glutathionylation in response to 
oxidative/nitrosative stress, its role as a fundamental component of the S-
glutathionylation process is limited. Compared with wild-type mice, only a subset 
of proteins with significantly altered peptide ratios were identified in GSTP-null 
mice [111].   
 
JNK Activation in Obesity and Diabetes 
 
The JNK signaling pathway is of prominent relevance to metabolic disease. JNK 
is a mitogen-activated protein kinase that can activate a variety of signal 
cascades through its phosphorylation of transcription factors [112].  In both 
dietary and genetic mouse models of obesity, exacerbated JNK activity 
potentiates IR in peripheral insulin-target tissues [113]. IR is attributed to multiple 
triggers such as increased pro-inflammatory cytokines, induction of ER stress 
and increased plasma free fatty acids [114]. At the molecular level, several 
stress-responsive serine/threonine protein kinases are activated by these stimuli, 
including JNK and inhibitor of nuclear factor-κB kinase (IKKβ), which both target 
the insulin receptor substrate (IRS)-1 for serine phosphorylation. As a result, IRS-
1 recruitment to insulin-bound insulin receptor is inhibited, thereby preventing 
activation of the insulin-signaling cascade. Consistent with this, JNK-deficient 
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mice are protected from HFD-induced obesity and IR [75, 115]. Furthermore, 
recent reports substantiate the involvement of JNK in insulin secretion in 
pancreatic β-cells [116-123]. JNK is involved in the loss of pancreatic β-cells 
induced by pro-inflammatory cytokines, and jnk1 deficiency or treatment with 
JNK inhibitors prevents IL-1β–induced apoptosis of islets and insulin-secreting 
cell lines [116, 124, 125]. Jnk1-deficient pancreatic islets show increased GIIS 
and protection against FFA-induced inhibition of glucose-triggered insulin gene 
transcription [117]. Moreover, JNK inhibition enhances the survival of islets 
subjected to transplantation protocols [121, 122]. Finally, JNK activation was 
sufficient to inhibit insulin receptor signaling but not elicit β-cell death and, hence, 
promote IR in pancreatic β-cells in vivo [126].  
 
SUMMARY AND PROJECT OBJECTIVES 
 
High-calorie diets have fostered the current pandemic of obesity and comorbid 
conditions of IR and diabetes. Efforts to better define the genetic and 
environmental risk factors are crucial. Obesity, diabetes and NAFLD are 
associated with dysregulation of glutathione S-transferases (GSTs). By virtue of 
its roles in aldehyde detoxification and JNK kinase regulation, the GST pi isoform 
is well poised to respond to oxidative and metabolic stress elicited by dietary or 
genetic nutrient excess. We hypothesized that the ability of GSTP to modulate 
JNK has a selective role in glucose homeostasis and served as the premise for 
the design of this study. Although epidemiological reports suggest this possibility, 
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there is no direct evidence for a functional involvement of GSTP in specific 
pathophysiological pathways that underlie the clinical features of diabetes.  
 
HYPOTHESIS: Decreased GSTP expression and/or function impairs systemic 
glucose handling and insulin sensitivity to promote progression towards impaired 
glucose tolerance via formation of increased protein-acrolein adducts and/or 
enhanced JNK phosphorylation to lead to blunted Akt signaling (Figure 1). To 
test this hypothesis, we conducted animal studies and addressed the following 
specific aims:                                                     
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FIG. 1. Hypothetical scheme of the postulated role of Glutathione S-
transferase P in glucose homeostasis via its function(s) in acrolein 
metabolism and JNK regulation. 
Consumption of high fat diet would result in the downregulation of the antioxidant 
enzyme, glutathione S-transferase P (GSTP) in metabolic tissues. Decreased 
GSTP abundance would lead to deficits in its function (s) of acrolein metabolism 
and JNK sequestration. Decreased acrolein metabolism would form increased 
protein-acrolein adducts that may have deleterious consequences for proteins 
critical for maintaining glucose homeostasis. Additionally, increased protein-
acrolein adducts could also lead to enhanced JNK activation via the ER-stress 
pathway. Distinct from its role in aldehyde metabolism, decreased GSTP in 
obesity could also result in increased JNK activation via inhibitory IRS-1/2 serine 
phosphorylation. JNK activation is well known to impair insulin sensitivity (and 
secretion) to lead to glucose intolerance via its effect on multiple pathways as 
outlined in the schematic. This may have implications for human polymorphic 
variants of GSTP with altered functionality. 
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SPECIFIC AIM 1: To determine the effects of early diet-induced obesity on 
GSTP expression and function in insulin-sensitive tissues.  
We assessed the effect of high fat diet on GSTP (and other GSTs) abundance, 
protein-acrolein adducts and phospho-JNK abundance in insulin-sensitive tissues 
in relation to glucose intolerance and IR in mice.  
 
SPECIFIC AIM 2: To define the contributions of GSTP in vivo to obesity, 
inflammation and blood glucose homeostasis.  
Next, we used whole-body GSTP-null mice to more directly evaluate the putative 
requirement of GSTP for blood glucose homeostasis. We determined the effects 
of GSTP-deficiency on body composition, glucose tolerance, insulin sensitivity 
and metabolic profiles under normal chow and high fat-fed conditions. These 
whole-body measurements were combined with assessment of phospho-JNK 
abundance and protein acrolein adducts to identify cellular mechanisms. To date, 
HFD-induced dysregulation in multiple GSTs have been reported, but none has 
yet demonstrated a role for a GST in glucose homeostasis in vivo.  
 
SPECIFIC AIM 3: To test the effect of JNK inhibitor, SP600125, on glucose 
homeostasis and inflammation in GSTP-null mice.  
Finally, we probed the role of JNK activation by testing the effect of JNK inhibitor, 
SP600125, on hepatic glucose output in GSTP-null mice.  
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Here, we show that hepatic GSTP is markedly suppressed in both dietary 
and genetic models of obesity-induced IR and that genetic deletion of GSTP 
leads to glucose intolerance. Furthermore, glucose intolerance in GSTP-deficient 
mice is due to increased hepatic glucose production mediated, at least in part, by 
insufficient insulin release and not IR. Finally, suppression of the JNK pathway 




This thesis is divided in five chapters representing the conceptual and 
experimental framework. Chapter I is a focused review of the literature relating to 
obesity, diabetes and glutathione-S-transferases as well as the thesis objective, 
approach to the hypothesis and the structure of the thesis.  Chapter II is a 
detailed description of the experimental procedures used for all studies.  Chapter 
III describes studies that apply the diet-induced obesity model to address 
Specific Aim 1. Chapter IV describes our efforts to explore the in vivo contribution 
of GSTP to obesity and diabetes by using GSTP-null mice to address Specific 
Aim 2. The chapter further describes the JNK inhibitor intervention study to 
address Specific Aim 3. Chapter V summarizes the overall conclusions derived 





CHAPTER II  
EXPERIMENTAL PROCEDURES  
Management of Mouse Colony. C57BL/6 and age-matched male db/db mice 
were purchased from the Jackson Laboratories (Bar Harbor, Maine, USA). All 
mice in the present study were housed either in the Research Resources 
Facilities located in the MDR (Medical Dental Resources) and Baxter II 
Biomedical Research Buildings at University of Louisville, Louisville, KY, USA. 
GSTP-null mice, generated on a MF1 background strain using homologous 
recombination [56], were bred for >12 generations with C57BL/6J mice as 
previously described [61]. Mice heterozygous for the targeted locus (F1) were 
crossed to generate wild-type (WT) and KO littermates. After weaning, genotypes 
were housed separately. Mice were housed at five or fewer per cage. Only male 
mice were used for experiments. Mice were fed normal chow diet (NCD, 12.5% 
kcal fat; catalog #D12450, Research Diets, New Brunswick, New Jersey, USA) 
unless otherwise specified. The GSTP-null mice were genotyped using primers 
that amplified the region between exons 5 and 6 of GSTP1 and a region in the 
lacZ gene to identify a null allele. The mice were healthy and reproduced in a 
Mendelian fashion. All animals were housed in specific pathogen-free facilities, in 
20–22°C temperature controlled rooms on a standard 12-h light and dark cycle 
and were allowed ad libitum access to water and food. All procedures involving 
mice were performed in accordance with the Declaration of Helsinki and with the 
Guide for the Care and Use of Laboratory Animals as adopted and promulgated 
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by the U.S. National Institutes of Health. All treatment protocols were in 
compliance with the University of Louisville IACUC.  
High Fat Feeding. Feeding of western diets in rodents induces body weight 
gain, adiposity and IR and is used as a model to study how nutrient excess elicits 
the progression of metabolic syndrome. It is well established that C57Bl/6 mice 
are “obesity prone” as well as are “susceptible to insulin resistance and glucose 
intolerance” [127].  Eight-week old male C57BL/6J and GSTP-null mice were fed 
normal chow (NC) diet or a high fat diet (HFD; 60% kcal, #D12492 Research 
Diets, New Brunswick, New Jersey, USA; 42% kcal, TD.88137, Harlan Teklad, 
Madison, Wisconsin, USA). In each group, a minimum total of 5 mice were used. 
Body weights and blood glucose (fasting and non-fasting) were recorded bi-
weekly. Body composition was assessed at 3 weeks, glucose tolerance tests 
were performed at 3.5 weeks and metabolic profile assessed at 5 weeks during 
the diet study (Figure 2).
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FIG. 2. Schematic illustrating the experimental design and end-points of 
diet-induced obesity study in WT and GSTP-null mice. 
Eight-week old male C57BL/6J and GSTP-null mice were fed normal chow (NC) 
diet or a high fat diet (HFD; 60% kcal, n=5-7 per group) for 6 weeks. Body 
weights were recorded bi-weekly. Body composition was assessed at 3 weeks by 
dual energy X-ray absorptiometry (DexaScan). Glucose tolerance test (GTT) was 
performed at 3.5 weeks and metabolic profile was assessed at 5 weeks during 
the diet study. At the end of the feeding protocol, mice were euthanized and 
blood (plasma) and tissues were harvested. Tissues such as liver, skeletal 
muscle and adipose depots representing visceral (epididymal, retroperitoneal), 
subcutaneous (white suprascapular) and brown (perivascular, PVAT; brown 









For the long-term HFD study, C57 mice fed NC or HF (60% kcal) for 16 weeks 
were purchased from Jackson Labs (n=5 per group). At the end of each feeding 
protocol, mice were euthanized (sodium pentobarbital i.p., 40 mg/kg body weight) 
and plasma and tissues were harvested. Animals were fasted for 6 h with free 
access to water, prior to euthanization. Tissues such as liver, skeletal muscle 
and adipose depots representing visceral (epididymal, retroperitoneal), 
subcutaneous (white suprascapular) and brown (perivascular, PVAT; brown 
interscapular, iBAT) adipose were harvested, weighed and snap-frozen (-80C) 
for further biochemical analyses. Sections of epididymal adipose and liver were 
formalin-fixed (10% neutral buffered formalin) for histological analyses of cell size 
or inflammatory cell infiltration.  Liver sections were embedded and frozen in 
OCT compound (optimal cutting temperature; Tissue-Tek-Catalog #4583; 
Thermo Fisher Scientific, Atlanta, Georgia, USA) at -80C for Oil Red O staining 
to assess lipid accumulation.  
Organ Analyses. Body and organ (liver, adipose tissue depots and heart) wet 
weights (nearest milligram) were recorded, and individual organs were snap-
frozen in liquid nitrogen and stored at -80°C. 
Fasting Blood Glucose Measurements. Blood glucose was measured using 
Accu-Check Aviva glucose monitor on blood collected from tail snips. Fasting 
regimens for blood glucose measurements in all our studies were performed 
according to recommended guidelines [128]. Since mice predominantly eat at 
night (dark cycle) and have a very high metabolic rate, overnight fasting a mouse 
is a major metabolic stress. Short-term fasting is more physiological and results 
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in reduced metabolic stress. A five- to six-hour fast is sufficient to assess whether 
fasting glucose levels are normal. Since mice tend to nibble throughout the day, 
mice rarely go into a “true” fast. Therefore, measuring glucose concentrations in 
the fed state is informative as well.  
Body Composition. Obesity is primarily a result of increased fat mass. To 
determine the effect of HFD on changes in lean and fat body mass, chow and fat-
fed mice were subjected to densitometry using Dual Energy X-ray 
Absorptiometry (DEXA). The DEXA scanner (PIXImus, LUNAR, Madison, WI, 
USA) offers a relatively non-invasive method to measure body composition in 
small rodents and is ideal for longitudinal studies requiring repeated 
measurements on the same mouse. Briefly, animals were anesthetized with 
isoflurane (5% for induction and 1–2% for maintenance), placed in the prone 
position, and scanned on the densitometer. Measurements included total mass, 
total fat mass, total lean mass, and body fat percentage. DEXA scans were also 
performed prior to all metabolic tests (GTT, PTT, and ITT) to enable 
glucose/pyruvate/insulin dosing based on lean body mass as recommended 
[128]. 
Metabolic Profile. The effect of HFD on metabolic profiles was evaluated by 
indirect calorimetry (TSE PhenoMaster System, Chesterfield, Missouri, USA). 
Volume of oxygen consumption (VO2) and carbon dioxide production (VCO2), as 
well as spontaneous locomotor activity, were simultaneously assessed in mice 
housed individually with free access to food and water. VO2 consumption and 
VCO2 production were measured every 10 min for a total of 24 h and was 
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normalized to body weight (and lean mass) to determine the respiratory quotient 
and energy expenditure. Food intake was determined continuously via scales 
located within the sealed-cage environment. Home-cage locomotor activity was 
determined using a multidimensional infrared light-beam system with beams 
scanning the bottom and top levels of the cage and activity being expressed as 
beam breaks. Data during the light and dark cycles were calculated separately. 
Metabolic Tests. Whole-body glucose homeostasis was assessed by 
intraperitoneal glucose tolerance test (GTT). The glucose tolerance test (GTT) 
measures the clearance of an intraperitoneally injected glucose load in conscious 
mice and is used to detect disturbances in glucose metabolism. The 
intraperitoneal Insulin Tolerance Test (ITT) is a variant of the GTT in which 
insulin is injected instead of glucose to assess the hypoglycemic effect of insulin 
as a measure of peripheral insulin sensitivity. The intraperitoneal Pyruvate 
Tolerance Test (PTT) is a variant of the GTT in which the gluconeogenic 
precursor, pyruvate, is injected instead of glucose.  
I. Glucose Tolerance Test. The GTT (intraperitoneal or oral) is commonly 
used in the diagnosis of diabetes in both humans and rodents. The ability 
to quickly normalize the hyperglycemia following injection of a glucose 
bolus provides integrated information about glucose-induced insulin 
secretion by the pancreatic β cells and insulin sensitivity in the liver and 
peripheral organs. Mice were fasted for 6 h with free access to water (8 
A.M.-2 P.M.). Each mouse was individually weighed immediately prior to 
glucose administration and glucose doses (D-glucose, Sigma Aldrich) 
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were calculated and prepared as a 1 mg/g lean body mass bolus in 100µl 
of total final volume in sterile saline. Mouse tails were gently cleansed and 
swabbed. A small incision was made at the tip of the tail for the collection 
of blood. An initial blood glucose level reading (t= 0) was taken prior to 
injection using the Accu-Chek Aviva Plus Glucose Meter. After the initial 
pre-glucose reading, mice were injected intraperitoneally with the 
predetermined dose. Glucose readings were recorded at 5, 15, 30, 60, 
120 min following the injection. The glucose readings were averaged 
within genotypes at each time point, giving the mean ± SEM. Glucose 
disposal was estimated by calculating the areas under the glucose 
disposal curves (AUC) using the trapezoidal rule. AUC was calculated by 
subtracting the average baseline area of each group from each individual 
AUC.  
II. Pyruvate Tolerance Test. Mice were fasted overnight for 16 h with free 
access to water. Each animal then received an intraperitoneal injection of 
pyruvate (2 mg/g lean body mass in 200µl of total final volume in sterile 
saline). Blood samples were taken from the tail vein before glucose 
injection (0 min) and at 15, 30, 60, 120 min after the injection.  The 30 min 
glucose appearance rate was calculated from the delta blood glucose 
values at 0 and 30 min respectively. The glucose readings were averaged 
within genotypes at each time point, giving the means ± S.E. Area under 
the curve for PTT was calculated similar to that of the GTT.  
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III. Insulin Tolerance Test. Age-matched mice were fasted for 6 h and then 
injected intraperitoneally with Humulin (1.5 units/kg, lean mass, Elli Lilly, 
Indianapolis, Indiana, USA). Glucose readings were recorded at 0, 30, 60, 
90, and 120 min post-injection. The glucose readings were averaged 
within genotypes at each time point, giving the means ± S.E.  
Insulin Signaling in vivo. To assess insulin sensitivity, mice were fasted for 6 h 
(3 A.M-9 A.M) and blood glucose was recorded (baseline; t = 0 min), following 
which an intraperitoneal insulin bolus (1.5U/kg lean body mass) was 
administered using sterile saline as diluent in a total volume of 100 µl per 
injection. After 15 min, blood glucose was recorded (t = 15 min) and skeletal 
muscle, liver and adipose were excised and snap frozen in liquid nitrogen. The ∆ 
blood glucose between 0 min and 15 min was calculated to assess insulin 
effectiveness. For analysis of insulin-stimulated PKB/Akt phosphorylation, tissues 
were pulverized in liquid nitrogen and homogenized in buffer A containing 
proteinase and phosphatase inhibitors. The homogenates were centrifuged at 
13,000 rpm for 20 min, and the supernatant protein (50 μg) was analyzed by 
SDS-PAGE and immunoblotting with antibodies that detect phospho-Akt 
(Ser473) and total Akt (Cell Signaling, Danvers, Massachusetts, USA), the distal 
end of the insulin signaling pathway.    
HOMA-IR and HOMA-β, as surrogate indices of insulin resistance and β-
cell function were computed as follows: HOMA-IR: fasting insulin (μIU/ml) × 
fasting glucose (mmol/ml)/22.5; HOMA-β:  20 × fasting insulin (μIU/ml)/fasting 
glucose (mmol/ml) − 3.5. 
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Glucose and Pyruvate-stimulated Insulin Secretion in vivo. The peak insulin 
secretion and action has been reported in the literature to be within ~25-30 min 
following glucose bolus administration in mice. The half-life of insulin in mice is 
~10-15 min and that of the pro-insulin cleavage product, C-peptide is ~30 min. 
Hence, we chose to address glucose-stimulated insulin secretion (GSIS) at two 
early time points, 20 min and 30 min post glucose bolus challenge in age-
matched WT and GSTP-null mice. Literature reports suggested that pyruvate-
stimulated insulin secretion and expression of gluconeogenic enzymes were 
altered at 60 min post injection [129]. Hence, we chose to address pyruvate-
stimulated insulin secretion (PSIS) at an early time point, 20 min (similar to GSIS) 
and at 60 min post pyruvate bolus challenge in age-matched WT and GSTP-null 
mice. Since baseline 6 h fasted plasma insulin values were not found to vary 
between WT and GSTP-null mice in multiple independent experiments, we 
considered it appropriate to examine the time points of GSIS and PSIS in 
separate cohorts of mice to decrease procedural stress of repeated blood 
sampling and enhance reliability of measurements. For each time point a 
minimum of 10 mice per group were used. As in all experiments with GSTP-null 
mice in our study, multiple litters were represented. Detailed schematic of the 
GSIS and PSIS protocol is presented in Figure. 3. Briefly, mice were fasted for 6 
h and administered a glucose or pyruvate bolus. Mice were anesthetized with 
sodium pentobarbital and blood (plasma) was collected and frozen at -80C for 
future insulin and c-peptide measurements at each time point of interest. Livers 
were also harvested and snap-frozen.
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FIG. 3.  Schematic illustrating the experimental design of glucose and 
pyruvate-stimulated insulin and C-peptide secretion in WT and GSTP-null 
mice. 
 WT and GSTP-null mice (n=10-12 animals per group) were fasted for 6 h or 16 h 
and were administered intraperitoneally a glucose (for GSIS) or pyruvate (for 
PSIS) bolus respectively. Mice were anesthetized with sodium pentobarbital and 
blood was harvested at indicated time points. Plasma was frozen at -80C for 












JNK Inhibitor Treatment in vivo. GSTP-null mice were separated into two 
groups with 12 animals in each group. Group 1 was vehicle control and littermate 
mice were included in Group 2 for treatment with the anthrapyrazolone inhibitor 
of JNK, SP600125 (Figure 4).  A total of nine cages were used for this study to 
represent mice from various litters. SP600125 was dissolved in dimethyl 
sulfoxide (DMSO) (Sigma) at a stock concentration of 20 mg/ml (optimal solubility 
of the drug in the solvent as reported by Sigma-Aldrich). The drug was 
administered at a dose of 5 mg/kg/day/injection, diluted with sterile saline such 
that the final total volume per injection remained 100 µl to avoid possible toxicity 
with higher injection volumes. The vehicle control consisted of DMSO diluted with 
sterile saline and was delivered in the same volume using BD Insulin Syringes 
(12.7 mm needle). Vehicle and SP600125 were administered by intraperitoneal 
injection once a day (P.M. except on day 7) for 7 continuous days. Proper 
dissolution of the drug in the solvent was ensured before each injection to avoid 
possible precipitation of the drug from the solution. Body weights of mice were 
recorded daily. Any loss in body weight equal to or more than 10 percent of their 
previous weight, perhaps due to effects of drug on food and drink intake, was 
considered a toxic effect and was set as an exclusion criteria for the study. To 
evaluate the effect of JNK inhibitor on hepatic gluconeogenesis, pyruvate 
tolerance test (PTT) was performed. Mice were fasted for 16 h overnight on day 
6, with free access to water. On day 7, baseline 16 h fasting blood glucose was 
recorded and final SP600125 injection was administered 
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FIG. 4.  Schematic illustrating the experimental design of JNK inhibitor 
intervention study in GSTP-null mice. 
 GSTP-null mice (n=12 animals per group) were treated intraperitoneally with 
JNK inhibitor (SP600125; 5 mg/kg, once daily) or vehicle (DMSO diluted with 
saline) for 7 consecutive days. Littermate mice were treated in pairs for all drug 
and vehicle injections. Body weights of mice were recorded daily to assess for 
potential drug toxicity. Animals were fasted overnight for 16 h on day 6 of the 
study for performing a pyruvate tolerance test (PTT) on day 7. On treatment day 
7, following the last drug injection, animals were administered a pyruvate bolus 
and blood glucose recorded at pre-defined time-points for the PTT. Mice were 
anesthetized immediately with sodium pentobarbital and euthanized. Blood 
(plasma) and liver were harvested and frozen at -80C. Blood was also used for 
complete blood count analysis
43 
 




in the A.M, 2 h following which PTT was performed. Mice were euthanized 
immediately and tissues (liver, skeletal muscle and epididymal adipose) and 
plasma were collected and stored at -80C for further biochemical studies. 100 µl 
of blood was used for complete blood count analyses.  
Complete Blood Cell Count. CBC was measured in blood collected from GSTP-
null mice from the JNK inhibitor study. Blood was sampled in 
ethylenediaminetetraacetic acid-containing tubes and leukocytes quantitated 
using a Hemavet.  
Protein Quantification by Immunoblotting.  
 
Protein abundance was measured in mouse tissue lysates by immunoblots using 
appropriate buffers.  
Buffer Composition.  
Buffer A (Tissue lysis buffer): RIPA buffer-10 mM Tris 7.2, 150 mM NaCl, 5 mM 
EDTA, 1% Triton X100, 1% sodium deoxycholate, 5 mM sodium orthovanadate, 
50 mM NaF, supplemented with 1:100 protease inhibitor mixture, 1:100 
phosphatase inhibitor mixture (Sigma Aldrich). 
Buffer B (Tissue lysis buffer): 25 mM HEPES, pH 7.0, 1 mM EDTA, 1 mM 
EGTA, 1% Nonidet P40, 1% SDS, supplemented with 1:100 protease inhibitor 
mixture, 1:100 phosphatase inhibitor mixture. 
Buffer C (Wash buffer and Antibody dilution buffer): TBST buffer was composed 
of 1X TBS (10 mM Tris 7.5, 150 mM NaCl) and 0.1% Tween 20. 
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Buffer D: 5X Laemmli buffer (312.5 mM Tris base, pH 6.8, 10% glycerol, 11.5% 
SDS, 0.1% bromophenol, and 50 mM N-ethylmaleimide)  
Stock solutions of running buffer and transfer buffer were prepared as 10X 
solutions and stored at room temperature prior to use. Stock solution of running 
buffer consisted of 10X Tris/Glycine/SDS Buffer. Stock solution of transfer buffer 
was made with 24.7 mM Tris and 191.8 mM glycine diluted in water to a 10X 
concentration. Working running buffer was prepared to a 1X concentration by 
dilution of 10X Buffer in Milli-Q water. Working transfer buffer was prepared at a 
1500mL volume composed of 300mL methanol, 150mL 10X transfer buffer, and 
1050uL MilliQ water. Prior to use, working transfer buffer was chilled for 15 
approximately 45 minutes at 4C.  
For GSTA, GSTM, GSTP, phospho-Akt and phospho-JNK Western blots: 
Frozen tissues (liver, skeletal muscle and adipose tissue) were pulverized using 
a metal tissue pulverizer that was cooled in liquid nitrogen. Aliquots of pulverized 
tissue were homogenized in buffer A to result in a 10 percent lysate (w/v), 
sonicated, and centrifuged (13,000 RPM, 20 min, 4°C). The lysate was sonicated 
for 10 seconds, and centrifuged at 13,000 RPM for 20 minutes. Protein 
concentration was determined in the supernatant using Bio-Rad reagents. 
Protein samples were prepared in buffer C with DTT (250mM) and heat-
denatured at 95°C for 10 min. Samples were subjected to SDS PAGE (120V), 
transferred to polyvinylidene fluoride membranes at 77 volts for 2 h at 4°C. The 
membranes were blocked with 5% BSA or milk in TBST for 1 h in room 
temperature followed by overnight incubation with primary antibodies: anti-
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phospho-SAPK/JNK; anti-SAPK/JNK; 1:1000 which recognizes both 46 and 54 
kDa JNK isoforms (Cell Signaling Technology, Danvers, Massachusetts, USA); 
GSTP (BD Biosciences, 1:1000, San Jose, California, USA); GSTA and GSTM 
(kind gift from Dr. R. Prough (Univ. of Louisville). The membranes that were 
probed for phospho-JNK and phospho-Akt were stripped with buffer D and 
incubated with antibodies for the respective total proteins or loading controls.  
For protein-acrolein adducts Western blots: Frozen tissues (adipose, liver, 
skeletal muscle) were pulverized and suspended in buffer B, sonicated, and 
centrifuged (13,000 rpm, 20 min, 4°C). Protein samples were prepared in buffer 
C without any reducing agents and heat-denatured at 95°C for 10 min. Samples 
were subjected to SDS PAGE, transferred to polyvinylidene fluoride membranes, 
blocked in 5% milk in TBST for 1 h at room temperature, and incubated overnight 
with an IgG-purified rabbit polyclonal antibody (1: 1000-2000) that recognizes 
keyhole limpet hemocyanin acrolein antigen (1:1000) (gift from Dr. P. Burcham, 
University of Western Australia). 
For all immunoblots, antibody binding was detected with appropriate secondary 
antibodies (anti-mouse HRP-conjugated IgG and anti-rabbit HRP-conjugated 
IgG; Cell Signaling).  All immunoblots were developed using chemiluminescence 
(ECL system (Pierce, Illinois, USA) and detected with a Typhoon 9400 variable 
mode imager (GE Healthcare). Quantification of band intensities was performed 
using Image Quant TL software (GE Healthcare).  
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Histology. For immunohistochemical staining, formalin-fixed, paraffin-embedded 
liver sections (5 μm) were stained with anti-GSTP1 antibody (1:1,500; 
Novocastra). 
Real-Time Quantitative PCR. RNA was isolated using Qiagen kit (Valencia, 
California, USA) and reverse transcribed using Bio-Rad (Richmond, California, 
USA) cDNA kit. QRT-PCR was performed with ABI Prism 7700 and SYBR green 
(Bio-Rad) detection of amplified products. Relative mRNA expression was 
estimated by the ∆∆Ct method [130] using Rplp0 as an internal standard [131]. 
GSTs were assessed using validated primers for Gstp1, Gstm4.1 and Gsta4, as 
representative isoforms of the respective GST class. All primer sequences for the 
GST isoforms, ER stress, inflammatory and gluconeogenic markers examined 
are provided in Table 1.
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Table 1. Oligonucleotide Primers  
 
Gene name Accession  # Forward primer Reverse primer 
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Biochemical Analyses. Plasma total cholesterol, HDL-cholesterol, LDL-
cholesterol and triglycerides were measured using respective reagents (Wako, 
Richmond, Virginia, USA) with the COBAS MIRA PLUS Analyzer (Roche 
Diagnostics, Indianapolis, Indiana, USA). Total hepatic cholesterol and 
triglycerides were extracted using the method of Bligh and Dyer (1959) [132] and 
measured using commercial reagents (Wako, Richmond, Virginia, USA).  Total 
hepatic GST conjugating activity towards the substrate 1-chloro-2,4-
dinitrobenzene (CDNB) was measured by a colorimetric assay (Cayman 
Chemicals, Ann Arbor, Michigan, USA). Plasma insulin and C-peptide levels 
were measured by commercial kits (Mercodia, Winston Salem, North Carolina; 
Crystal Chem, Downers Grove, Illinois, USA respectively). To measure fasting 
plasma insulin levels, mice were fasted for 6 h. Blood was collected from 
anesthetized mice by left ventricular cardiac puncture and centrifuged at 3,000 × 
g for 20 min. The clarified plasma layer was transferred to a new tube, snap-
frozen, and stored at –80 °C. On the day of the assay, the plasma samples were 
thawed and centrifuged (4000Xg, 5 min at 4C). Standard curves were performed 
with each assay. Assays were performed in duplicate, and the insulin/C-peptide 
values for all of the replicates of a single sample were calculated and the 
averages for all samples within a treatment or genotype group were used to 
calculate the means ± SEM. The lower limit of detection for the insulin assay was 
0.025μg/L for a 25 μl sample.  
Liver Triglycerides and Total Cholesterol. To examine hepatic lipid 
accumulation, total hepatic cholesterol and triglycerides were extracted using the 
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method of Bligh and Dyer (1959) and measured using commercial reagents 
(Wako, Richmond, Virginia, USA).   
Statistical Analysis. Statistical analyses were performed using GraphPad Prism 
software (La Jolla, California, USA). Data are presented as mean ± SEM. 
Comparisons between two groups were performed by Student’s t-test or Mann-
Whitney U-test while multiple groups were compared using one-way or two-way 
ANOVA with Bonferroni’s post hoc test as appropriate. Spearman’s Rank 
Correlation Coefficients were computed using R software [133]. P< 0.05 was 









Obesity and type 2 diabetes (T2D) are major public health concerns worldwide. 
While lifestyle choices and lack of exercise are important risk factors for weight 
gain, high calorie diets are a key factor fueling the current pandemic of obesity 
and comorbid conditions of non-alcoholic fatty liver disease (NAFLD), systemic 
insulin resistance (IR) and T2D [1-4]. Poor dietary habits promote a cluster of risk 
factors for development of T2D and cardiovascular disease. More than one-third 
(34.9% or 78.6 million) of U.S. adults are obese and 68% are overweight or 
obese [5]. According to the CDC reports in 2015, nearly 30 million Americans 
have diabetes [134]. However, not all obese individuals develop cardiometabolic 
abnormalities, suggesting that key environmental/genetic factors contribute to the 
development of IR [18, 19]. For example, NAFLD and/or T2D are reported in an 
estimated 60% of the urban population including young, lean individuals in Asian 
communities [2, 10]. Likewise, several studies in rodents indicate that obesity 
and insulin resistance may be distinct sequelae of nutrient excess. Given that 
obesity, thus, is not a prerequisite for development of diabetes, the early 
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metabolic changes governing interindividual susceptibility need to be 
investigated.  
Accumulating evidence suggests that obesity, NAFLD and diabetes are all 
linked with aberrant hepatic expression of glutathione S-transferase (GSTs) 
isozymes [40, 49, 135]. The GSTs are a multigene family of abundant and 
ubiquitous phase II enzymes [36] that primarily catalyze glutathione (GSH) 
conjugation of toxic, unsaturated aldehydes such as acrolein and 4-
hydroxynonenal (4HNE). Given that consumption of high calorie diets results in 
oxidative stress-mediated metabolic formation of 4-HNE and acrolein [45, 46], a 
loss of GST activity in vivo may be detrimental. Consistent with this idea, 
downregulated GSTA in obese, insulin-resistant humans or HFD-fed mice results 
in increased protein-HNE adducts (carbonylated proteins) in adipose [45, 46]. 
Furthermore, human GSTM1, GSTT1 and GSTP1 gene polymorphisms (i.e., 
altered GST activity) [80, 81] are associated with increased risk of T2D [84, 88, 
89, 136]. Accumulation of protein-aldehyde adducts, which can diminish protein 
function and trigger endoplasmic reticulum (ER) stress [98, 137], is a proposed 
mechanistic link between oxidative stress, inflammation and IR [45, 46]. 
Considered together, altered GSTs may represent an early causal change that 




The GST Pi (GSTP) isoform has diverse catalytic and non-catalytic functions 
potentially relevant to metabolic disease [36]. For example, GSTP specifically 
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catalyzes GSH conjugation to acrolein facilitating its detoxification [95]. Similarly, 
diet-induced obesity in mice downregulates hepatic GSTP [49], increases levels 
of tissue and plasma protein–acrolein adducts [100], and urinary acrolein level 
correlates with glycated hemoglobin in T2D subjects [101]. Distinct from its 
catalytic function, GSTP binds and inhibits c-Jun NH2-terminal kinase (JNK) 
activation [102]. GSTP-null mice exhibit constitutive JNK activation in liver and 
lung [107]. Moreover, excessive JNK activation in response to multiple triggers 
mediates IR [114, 138, 139], and JNK-deficient mice are protected from HFD-
induced obesity and IR [75, 113, 115]. The specific role of GSTP in JNK 
activation and development of insulin resistance has not been addressed. Thus, 
we hypothesized that GSTP dysregulation contributes to metabolic 
derangements of diet-induced obesity, perhaps through protein-acrolein adduct 
formation and/or JNK activation. Using the commonly used diet-induced obesity 
model in mice, we studied effects of high fat diet on GSTP abundance and 




Short-term high fat diet leads to increased adiposity, insulin resistance, 
glucose intolerance and altered systemic metabolism.  
Numerous studies indicate that GSTs are dysregulated in diet-induced obesity 
and in human NAFLD, yet whether altered GSTs are mechanistically involved in 
the development of glucose intolerance is unclear. So, to gain insight, eight 
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week-old male C57BL/6J (WT) mice were fed NC or HFD (60 kcal% fat), with ad 
libitum access to both diets. Four days into the diet regimen, mice on the HFD 
exhibited significantly greater weight gain (1.04 ± 0.09 g in NC, 2.84 ± 0.16 g in 
HF, p<0.05, n=5) which persisted throughout the six weeks of the diet study (Fig. 
5A). Since obesity is primarily a result of increase in fat mass, mice were 
subjected to DEXA at 3 weeks to estimate body composition. Dexascan analysis 
showed a 2-fold increase in fat mass in HF-fed mice compared to chow-fed mice 
(Fig. 5B), typical of this commonly utilized model of diet-induced obesity [127]. 
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FIG. 5.  Short-term diet-induced obesity in WT mice. 
(A) Absolute weekly body weight (BW) of mice fed normal chow (NC) and high-
fat diet (HF, 60% kcal fat) ad libitum for 6 weeks. Dual-energy X-ray 
absorptiometry (DEXA) analysis and glucose tolerance test (GTT) were 
performed at 3 or 3.5 weeks of diet study, respectively (see arrows). (B) Lean 
and fat mass content as measured by DEXA. Inset: Representative DEXA 
images. (C) Fed and (D) Fasting (6h) blood glucose at weeks 2 and 3 of diet 
study measured by tail vein. (E-J) Organ to body weight ratios at the end of the 
diet study. Values are mean ± SEM (n = 5 per group). BW, body weight; EWAT, 
epididymal white adipose tissue; SubQ WAT, subcutaneous white adipose tissue; 
BAT, brown adipose tissue (interscapular); PVAT, perivascular adipose tissue. 
*P< 0.05, NC vs. HF by Mann-Whitney U test. NC, open symbols or bars; HF, 
filled symbols or grey bars.   
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Figure 5. Diet-induced obesity in WT mice  
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As a primary screen to evaluate glucose homeostasis, fasted and fed 
blood glucose was measured each week.  After 3 weeks of HF feeding, we 
observed a significant elevation in fasting blood glucose concentrations in obese 
mice compared with controls (NC, 133.8± 6.176 mg/dL vs HF, 184.2 ± 15.47 
mg/dL, n=5 per group, p<0.05; Fig. 5D), suggesting onset of glucose intolerance 
or insulin insensitivity. Therefore, to examine the glucose tolerance status, GTT 
was performed. Following a six hour fast, mice were administered an 
intraperitoneal glucose bolus (1 mg/g lean mass) to evaluate blood glucose 
excursions. Since the primary site of glucose disposal, skeletal muscle (lean 
mass), is relatively unaltered by HF feeding, it is recommended to normalize 
glucose doses on the basis of lean mass and not total body weight to avoid 
overdosing obese animals [128] . Our serial use of DEXA enabled estimation of 
lean mass to calculate glucose doses for GTT studies. Mice fed HF for 3.5 weeks 
demonstrated worsened glucose tolerance compared with chow-fed mice, as 
assessed by GTT AUC (NC, 5406 ± 953.6  mg/dL*time vs. HF, 10870 ± 868.2 
mg/dL*time, n = 5 per group, p<0.05; Fig. 6A-B). Consistent with IGT, surrogate 
markers of IR such as fasting plasma insulin, HOMA-IR and HOMA-β were also 
elevated in obese mice (Fig. 6D-F). 
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FIG. 6.  Short-term diet-induced obesity and glucose intolerance in WT 
mice. 
  
Glucose tolerance test (GTT), glycemic indices and indirect calorimetry 
measurements shown for WT mice fed NC and HF diet. (A) For GTT, mice were 
fasted for 6 h and injected intraperitoneally with glucose bolus (1 mg/g of lean 
mass), blood glucose measured by tail vein, and (B) the area under the curve 
(AUC) was calculated. (C) Fasting blood glucose (6 h) and (D) plasma insulin 
concentrations were measured from blood collected at the end of the diet study. 
(E) HOMA-IR and (F) HOMA %β were calculated from fasting blood glucose and 
insulin as described. Metabolic parameters were measured by indirect 
calorimetry in 12 week-old WT and GSTP-null mice using a PhenoMaster 
system: (G) oxygen consumption (VO2); (H) carbon dioxide production (VCO2); 
(I) respiratory exchange ratio (RER); (J) total activity (movement); and (K, L) 
food and water intake. Values are mean ± SEM (n = 5 per group). HOMA-IR and 
HOMA-%β, homeostasis model assessment-estimated insulin resistance and β-
cell function indices. *P< 0.05, NC vs. HF by Mann-Whitney U test. NC, open 








To determine how diet affects systemic metabolism, mice fed either NC or 
HFD for 5 weeks were placed in metabolic chambers to assess metabolic profile 
by indirect calorimetry. Measurements included oxygen consumption (VO2), 
carbon dioxide production (VCO2), food and water intake, and physical activity. 
As shown in Fig. 6F and G, average VCO2 values were decreased in HF-fed 
mice compared with mice fed NC. The respiratory exchange ratio (RER) was 
also decreased in mice fed HF compared with NC-fed mice (Fig. 6H). Physical 
activity, measured by total beam breaks (Fig. 6I), ambulatory counts (Fig. 6J), 
and fine movements (Fig. 6K), was not significantly different between groups. 
Effect of obesity on glutathione-S-transferase expression and activity in 
insulin-responsive tissues.  
To evaluate HFD effects on GSTs, we measured mRNA and protein abundance 
of major GST isozymes in insulin-responsive tissues. The mRNAs of the GST 
family (Gsta4, Gstm4.1 and Gstp1) were decreased in livers of mice fed HFD (6 
weeks, 60% kcal) compared with NC (Fig. 7A-C).  Western blotting for GSTA, 
GSTM, and GSTP confirmed mRNA data (Fig. 7D-E). Surprisingly, GSTP 
abundance was not diminished by HFD in skeletal muscle and epididymal 
adipose tissue (Fig. 3G). In addition, we also found a significant decrease in 
GSTP protein abundance and total GST activity in interscapular brown adipose 
tissue (BAT) which may have implications for BAT inflammation and 
mitochondrial function (Fig. 3I, J and K). Similarly, hepatic GSTP protein was 
significantly decreased in both WT mice fed a different HF composition (42% 
kcal; 4-12 weeks) and in diabetic db/db mice (∼70%; Fig. 8A, B). Consistent with 
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HFD-induced downregulation of GSTP protein, positive GSTP 
immunohistochemical staining was substantially decreased (and restricted to 
portal triad region) in livers of HFD-fed mice (42% kcal; 12 weeks; Fig. 8C-D). 
Furthermore, hepatic total GST activity towards the substrate CDNB and GSTP-
specific activity (for substrate, ethacrynic acid) was significantly decreased in 
mice fed HF (42% kcal) for 12 weeks (Fig. 8C, D). To summarize, hepatic GSTP 
abundance and GST activity were markedly reduced in both HFD-induced and a 
genetic model of obesity and IR. Overall, these data are consistent with prior 
measurements of hepatic GSTs in fat-fed animals [49] and collectively illustrate 
the significance of hepatic GST suppression as an early change that can 
augment susceptibility to diet-induced glucose intolerance
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FIG. 7. Short-term diet-induced obesity and Glutathione S-transferases 
(GST) expression and activity in insulin-sensitive organs. 
 
(A) Gsta4, (B) Gstm4.1, and (C) Gstp1 mRNA expression (normalized to Rplp0) 
in liver of NC and HF-fed C57BL6/J mice (n=6-8 per group). (D) Representative 
Western blots of liver lysates for GSTA, GSTM and GSTP and respective (E) 
densitometric analyses (n=5-13 per group). (F) Hepatic GST activity measured 
with 1-chloro-dinitrobenzene (CDNB) as substrate (n=10-11 per group). 
Representative Western blots for GSTP in (G) gastrocnemius skeletal muscle 
(SKM), epididymal white adipose tissue (WAT) and (I) interscapular brown 
adipose tissue (BAT)  lysates and (H, J) densitometric analyses. (K) GST activity 
in BAT measured with CDNB as substrate. “Null” indicates liver homogenate of 
GSTP-null mice used as negative control. Values are mean ± SEM. *P< 0.05, NC 
vs. HF or vs db/db by Mann-Whitney U test. NC, open symbols or bars; HF, filled 
symbols or bars.  
63 
 




FIG. 8. Long-term diet-induced obesity and hepatic GSTP expression and 
activity in WT mice.  
 
(A) Hepatic GSTP abundance in C57BL/6J mice fed either a NC or HF diet (42% 
kcal fat) for 4–12 weeks, and GSTP in age-matched db/db mice, and (B) 
densitometric analyses (n=3 per group). (E, F) Representative histology images 
of immunohistochemical staining for GSTP in livers of NC and HF (42% kcal, 12 
weeks, 100X). Hepatic GST activity measured with (E) 1-chloro-dinitrobenzene 
(CDNB) and (F) and ethacrynic acid as substrate in NC and HF-fed mice from 
the 12 weeks cohort (n=6 per group). Values are mean ± SEM. *P< 0.05, NC vs. 




Figure 8. Effect of HFD on hepatic GSTP in WT mice 
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Effect of prolonged high fat diet on GSTP abundance in adipose depots. 
In separate studies, we investigated the effect of long-term high fat feeding (16 
weeks, 60% kcal) on GSTP abundance in adipose tissues depots in WT mice. 
Our rationale to study depot-specific effects was based on the knowledge that, 
not all adipose depots are equally susceptible to inflammation and do not confer 
the same risk of CVD in obese, diabetic individuals. Visceral adipose tissue 
(VAT) confers a higher risk of metabolic syndrome and incident cardiovascular 
disease than subcutaneous adipose (SAT). Recently, perivascular adipose tissue 
(PVAT) has been proposed to be a potential link between diabetes and CVD. 
Also, brown adipose tissue (BAT) transplantation significantly decreased body 
weight and improved glucose metabolism and insulin sensitivity. Therefore, we 
evaluated whether long-term HFD affected GSTP abundance differently in 
adipose depots compared with NC-fed mice. Similar to short-term HFD, GSTP 
abundance was unaltered in epididymal adipose tissue, but was significantly 
decreased in BAT (Fig. 9A, B). Interestingly, decrease in GSTP abundance was 
also observed in subcutaneous and perirenal adipose tissue. Furthermore, we 
confirmed that GSTP was present in the adipocyte fraction of adipose tissue (Fig. 
9E). Potential implications of GSTP dysregulation in adipose depots in obese 
states remain to be investigated. 
67 
 
FIG. 9. Long-term diet-induced obesity and protein abundance of GSTP in 
adipose tissue depots in WT mice.  
 
Normal chow (NC) and high fat diet (HF)-fed (60% kcal fat, 16 weeks) C57BL/6J 
mice were purchased from JAX (n=4 per group). Representative Western blots 
for GSTP in (A) epididymal white (EWAT), (B) interscapular brown (BAT), (C) 
subcutaneous white (SubQ-WAT) and (D) perirenal white adipose tissues and 
respective (F) densitometric analyses. (E) Western blot for GSTP in lysates from 
epididymal white adipose tissue (EWAT) and adipocyte (AF) and stromal 
vascular fraction (SVF). Values are mean ± SEM. *P< 0.05, NC vs. HF or vs 




Figure 9. Effect of HFD on adipose depot GSTP in WT mice  
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Obesity results in increased protein-acrolein adduct formation and JNK 
activation in the liver. 
Because GSTs are multifunctional proteins that contribute to the metabolism of 
environmentally-, drug- and lipid-derived toxic aldehydes, such as acrolein and 
4HNE [36], yet also modulate stress signaling, e.g., JNK [102], we hypothesized 
that decreased GST abundance may deleteriously alter one or both of these 
pathways in livers of HFD-fed mice.  
Insufficient GSTP activity may induce deficits in acrolein metabolism 
leading to increased accumulation of protein acrolein adducts. Acrolein-induced 
protein crosslinking can inhibit protein function or affect protein folding leading to 
ER stress and the unfolded protein response (UPR) [98]. Indeed, recent studies 
have demonstrated acrolein-induced ER stress and UPR. ER stress-activation of 
JNK is a link between obesity, inflammation and insulin resistance [138, 140]. 
Consistent with our hypothesis, HFD compared with NC significantly increased 
abundance of several hepatic protein-acrolein adducts, i.e., Mr 125 kDa, +2.5 
fold; Mr 77 kDa, +2.0 fold and Mr 27 kDa, +1.5 fold  (Fig. 10A). Relative 
abundance of adducts was quantified by normalizing the intensity of the specific 




FIG. 10. Protein-acrolein adducts in normal chow and high-fat diet fed WT 
mice.  
Representative Western blots of protein-acrolein adduct bands in (A) liver, (C) 
gastrocnemius skeletal muscle, and (E) epididymal adipose tissue and respective 
(B, D, F) densitometric analyses. Values are mean ± SEM (n=5 per group). *P< 
0.05, NC vs. HF by Mann-Whitney U-test. NC, open bars; HF, filled bars.  
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This HFD effect was selective for the liver as levels of protein-acrolein adducts 
were unchanged in adipose and skeletal muscle (Fig. 10B, C) – organs where 
GSTP was not downregulated by HFD.  
Given that GSTP limits JNK activation and signaling [102, 107] and that 
activated JNK inhibits insulin signaling [139], we assessed JNK phosphorylation 
status in HFD-fed mice. As shown in Fig. 11A-C, hepatic phospho-p54 JNK (but 
not phospho-p46) abundance was increased ~3-fold in livers of HFD-fed mice vs 
NC-fed mice. Hepatic phospho-p54 JNK abundance was also correlated 
positively with GTT AUC (Fig. 11D) – an unsurprising finding given the known 
inhibitory role of JNK and insulin signaling [139].  
Collectively, these data support a model wherein, the lean to obese 
transition results in impaired glucose tolerance, fasting hyperinsulinemia and 
increased HOMA-IR, coincident with hepatic GSTP downregulation, increased 
JNK phosphorylation and protein-acrolein adduct formation. However, because 
multiple GSTs were downregulated by even a short-term feeding of HFD, it is 
unclear whether metabolic derangements can be solely attributed to a decrease 
in GSTP alone. Therefore, we next tested whether GSTP deficiency alone 
(GSTP-null mice) could recapitulate the phenotypic effects of short-term HFD on 
glucose tolerance as described in chapter IV. 
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FIG. 11. High-fat diet-induced phosphorylation of JNK in WT mice.  
 
Representative Western blots for phospho-JNK (Thr183/Tyr185) and total JNK 
(p54/p46) in (A) liver, (E) gastrocnemius skeletal muscle, and (F) epididymal 
white adipose tissue from NC- and HF-fed WT mice and respective densitometric 
analyses (B, C, G, H). (D) Hepatic phospho-p54 JNK protein band density was 
plotted against GTT AUC (r2=0.3, p<0.05). Values are mean ± SEM (n=5 per 
group). *P< 0.05, NC vs. HF by Mann-Whitney U-test. NC, open symbols or bars; 
HF, filled symbols or bars.  
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The major findings of this study are that short-term high fat diet feeding in mice 
significantly downregulates several GST proteins including GSTP (by an as yet 
undefined mechanism). Glucose intolerance in HFD-fed mice is correlated with 
amount of hepatic phospho-p54-JNK (activated). Furthermore, obese mice 
demonstrate markedly elevated hepatic protein-acrolein adducts, in agreement 
with the known function of GSTP in acrolein metabolism. Collectively, we 
conclude that downregulation of hepatic GSTP selectively increases JNK 
activation and induces deficits in aldehyde detoxification that, in turn, alters liver 
metabolism to promote glucose intolerance.  We believe this scenario represents 
an early event that begets a “domino” type cascade of deleterious events leading 
from diet-induced obesity to diabetes. 
In the current study, we provide evidence that hepatic GSTs are involved 
in the early derangements in obesity. High fat diet suppressed GSTP isozyme in 
the liver but not in the epididymal adipose or the skeletal muscle of WT mice. 
GSTA protein was selectively downregulated in adipose tissue of obese mice, 
suggesting a tissue-specific metabolic role of GSTs in obesity and diabetes [45, 
46]. Second, we show that, phospho-JNK abundance (p54 but not p46) is 
selectively increased in the livers of HFD-fed (only 3.5 weeks) WT mice. 
Moreover, the level of phospho-JNK is positively correlated with the level of 
glucose intolerance (see Fig. 11D). Because GSTP inhibits JNK in vivo [107], we 
infer that hepatic GSTP downregulation contributes to hepatic JNK activation and 
progression towards IGT in obesity. Although augmented JNK activation in 
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peripheral tissues is known to mediate glucose intolerance and IR [139], these 
models do not address the earliest events that precede established systemic IR.   
A potential factor known to induce JNK activation is the accumulation of 
aldehyde-modified proteins (carbonylated proteins), and protein-aldehyde 
adducts are considered determinants of inflammation and IR [30, 46]. A primary 
role for GSTP is as an antioxidant enzyme, quenching acrolein in the cell. 
Because GSTP activity selectively conjugates GSH with acrolein [52], we 
measured and found increases in protein-acrolein adducts in liver (but not in 
skeletal muscle nor in adipose) of short-term HFD-fed WT mice compared with 
NC-fed mice (Figs 10A). Interestingly, a general pattern of protein-acrolein 
adducts (5 prominent Mr bands: 125, 90, 77, 75, 27 kDa) appears following HFD 
and some of these bands are significantly increased. While the role of these 
adducts in JNK activation is unclear, the accumulation of these adducts reflects a 
loss of acrolein removal capacity that is consistent with the decreased overall 
GSTP abundance and GST activity (using CDNB as substrate), in livers of HFD-
fed WT mice. Previously, we used organ-specific protein-acrolein adducts as 
both a metric of acrolein exposure (as with tobacco smoke; [59]) but also as an 
arbiter of cardiac injury in models of ischemia-reperfusion [61] and 
cyclophosphamide toxicity [62].  Whereas other studies have demonstrated an 
increase in oxidative stress markers such as hepatic malondialdehyde and ROS 
measurements [141], to our knowledge this is the first report of direct protein 
modification by acrolein in liver, linked to obesity. Modest but multiple protein 
modifications common to a pathway or process has been deemed sufficient to 
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alter overall metabolic flux in an organ [46]. Acrolein-adduction can inhibit protein 
function or affect protein folding leading to ER stress and the UPR [98]. ER 
stress-activation of JNK is a link between obesity, inflammation and IR. The 
potential direct relationship between protein-acrolein adducts and JNK activation 
remains to be investigated. Further studies should determine targets of acrolein 
crosslinking in liver, the specific modification and its functional consequences. 
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FIG. 12. Schematic illustrating the effect of high fat diet on GSTP 
abundance and function in WT mice.  
Effects of high fat (HF) diet in wild-type (WT) are shown with blue arrows. HF diet 
results in glucose intolerance in WT mice, typical of this commonly utilized model 
of diet-induced obesity [127]. In the liver, HF feeding decreases GSTP protein 
and total GST activity concomitant with increased protein-acrolein adduct and 
phospho-JNK abundance, in agreement with the known functions of GSTP [36, 
102]. Hepatic phospho-p54 JNK positively correlates with glucose intolerance in 
HF-fed mice. Because GSTP is an in vivo JNK inhibitor [107], decreased hepatic 
GSTP could augment JNK activation following early diet-induced obesity
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In summary, we show that short-term HFD-induced glucose intolerance in 
mice is concomitant with decreased GSTP abundance and increased phospho-
p54 JNK and accumulation of protein-acrolein adducts in murine livers. Because 
GSTP is normally expressed at low levels in human liver [54] and is highly 
polymorphic [36], further studies of diet-induced hepatic GSTP dysregulation in 
human obesity, NAFLD and diabetes are warranted.  Preventing even small 
changes in hepatic GSTP abundance or activity may have potentially important 










Glucose metabolism lies at the heart of type 2 diabetes (T2D). T2D is 
characterized by deregulation of glucose homeostasis through the development 
of insulin resistance, manifested as diminished glucose uptake in peripheral 
tissues and increased glucose production in the liver. The phenomenon of insulin 
resistance encompasses a precise sequence of events that mediate the hormone 
signal into action in peripheral tissues.  
Insulin Signaling 
Binding of insulin to the insulin receptor, a membrane tyrosine kinase, leads to its 
dimerization and self-phosphorylation of specific intracellular tyrosine residues. 
This phosphorylation event initiates a protein signaling cascade in peripheral 
tissues that culminates in mediating the effects of insulin on multiple cellular 
metabolic pathways. Akt is a serine threonine kinase which lies at the distal end 
of the insulin signaling cascade and mediates many of insulin’s metabolic effects 
through phosphorylation of various targets including protein kinases, transcription 
factors and enzymes. 
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Insulin action in the liver is pivotal for the control of glucose metabolism. The 
effect of insulin to inhibit hepatic glucose production (HGP) is essential for 
glucose homeostasis. Hepatic insulin resistance and impaired suppression of 
HGP underlies the hyperglycemia in patients with diabetes [142].  
Biochemistry of Hepatic Glucose Production 
Two metabolic pathways contribute to glucose production in vivo: glycogenolysis 
in the liver and gluconeogenesis in the liver and kidney. As prolonged fasting 
depletes the glycogen stores, gluconeogenesis provides the required glucose 
from multiple metabolic sources. I will describe the pathway of gluconeogenesis 
alone to remain within the confines of the experimental framework of this thesis. 
Gluconeogenesis 
Hepatic gluconeogenesis is responsible for the de novo production of glucose 
from three carbon precursors such as glycerol, lactate, pyruvate and alanine. 
Gluconeogenesis operates exclusively in the hepatocytes and the renal cortex. 
Figure 13 highlights the reactions within the pathway. Gluconeogenesis is often 
described as the “reverse of glycolysis”. Glycolysis is highly exergonic resulting in 
the generation of pyruvate, ATP and NADH with several enzymes catalyzing 
thermodynamically irreversible reactions. Gluconeogenesis utilizes a combination 




FIG. 13. Schematic showing the biochemical reactions of the 
gluconeogenesis pathway (adapted from Voet and Voet). 
Gluconeogenic pathway enzymes are analogous to their glycolytic counterparts, 
with exception of reaction steps that are thermodynamically unfavorable. In the 
first committed step of gluconeogenesis, pyruvate carboxylase (EC 6.4.1.1) 
catalyzes the synthesis of phosphoenolpyruvate (PEP) from pyruvate. 
Phosphoenolpyruvate carboxykinase (PEPCK, EC 4.1.1.32) catalyzes the 
decarboxylation of cytosolic oxaloacetate into phosphoenolpyruvate, after 
transport from the mitochondria through the oxaloacetate-malate shuttle. At this 
point, PEP undergoes the reversible reactions of gluconeogenesis into the triose 
phosphate pool, condensation through aldolase and formation of fructose-1,6-
bisphosphate. Fructose-1,6-bisphosphatase (EC 3.1.3.11) catalyzes the removal 
of the C1 phosphate and formation of fructose-6-phosphate. The last step in the 
metabolic pathway of gluconeogenesis is the dephosphorylation of glucose-6-
phosphate through the action of glucose-6-phosphatase (EC 3.1.3.9). 
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Figure 13. Scheme: Biochemical pathway of gluconeogenesis  
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Gluconeogenic pathway enzymes are analogous to their glycolytic complements, 
with exception of reaction steps that are thermodynamically unfavorable. In the 
first committed step of gluconeogenesis, pyruvate carboxylase (EC 6.4.1.1), 
found in liver and kidney but not muscle, catalyzes the synthesis of 
phosphoenolpyruvate (PEP) from pyruvate. Phosphoenolpyruvate carboxykinase 
(PEPCK, EC 4.1.1.32) catalyzes the decarboxylation of cytosolic oxaloacetate 
into phosphoenolpyruvate, after transport from the mitochondria through the 
oxaloacetate-malate shuttle. As with pyruvate carboxylase, PEPCK is found in 
liver and kidney cells. PEP undergoes the reversible reactions of 
gluconeogenesis into the triose phosphate pool, condensation through aldolase 
and formation of fructose-1,6-bisphosphate. Fructose-1,6-bisphosphatase (EC 
3.1.3.11) catalyzes the removal of the C1 phosphate and formation of fructose-6-
phosphate. This enzyme is again found in the liver and kidney. The last step in 
the pathway of gluconeogenesis is the dephosphorylation of glucose-6-
phosphate through the action of glucose-6-phosphatase (EC 3.1.3.9). This 
enzyme is again exclusive to liver and kidney. These enzymes are used as 
markers for gluconeogenesis given their distinctive presence in this pathway. 
Excess hepatic glucose output has been attributed to dysregulation of the 
gluconeogenic enzymes, PEPCK and G6Pase [143]. Insulin inhibits the 
transcriptional expression of both of these enzymes through Akt-mediated 
phosphorylation of FoxO1 [144]. Phosphorylation of the FoxO proteins resulting 
in their translocation from the nucleus and sequestration in the cytoplasm results 
in the inhibition of gluconeogenic gene expression. The promoters of both the 
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PEPCK and G6Pase genes contain so called insulin responsive elements (IREs) 
that are essential for the effect of insulin on the regulation of those genes.  
During the initial stages of fasting, gluconeogenesis accounts for roughly 
25% of the glucose output. Upon exhaustion of glycogen reserves, 
gluconeogenesis becomes the principal source of glucose. The primary glucose 
sources include lactate from cellular respiration, alanine from protein breakdown 
and glycerol from triglyceride breakdown. Precise mechanisms of control for 
gluconeogenesis have been postulated which include: availability of precursors 
and their initial conversion to the first metabolic intermediate, conversion of 
pyruvate to phoshoenolpyruvate and the conversion of fructose-1,6-bisphosphate 
to fructose-6-phosphate. 
Glucose-stimulated Insulin Secretion 
Pancreatic insulin secretion from the β-cells follows a biphasic pattern, in which 
an initial peak minutes after stimulation by glucose is followed by a lower 
magnitude sustained phase over the duration of glucose stimulation. This 
phenomenon is contributed by the interaction of two signaling pathways: the 
triggering pathway and the amplifying pathway [145, 146]. In the triggering phase 
of insulin secretion, mitochondrial glucose metabolism leads to an increase in 
cytosolic ATP/ADP ratio, which causes the closure of the ATP-sensitive K 
channel (KATP channel) and membrane depolarization. The resulting membrane 
depolarization opens voltage-dependent calcium channels, allowing an influx of 
extracellular Ca2+ and stimulation of calcium-induced calcium release from the 
endoplasmic reticulum. This leads to ATP-dependent exocytosis of a readily 
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releasable pool of insulin granules. The amplifying pathway of insulin secretion is 
also dependent on glucose but does not elevate the intracellular Ca2+ 




Our previous work (Chapter III) shows that obesity-induced insulin resistance and 
impaired glucose tolerance is concurrent with hepatic GSTP downregulation and 
increased JNK phosphorylation and protein-acrolein adducts. However, multiple 
GSTs were dysregulated by even a short-term feeding of HFD. To more fully 
explore the role of GSTP in glucose homeostasis, we compared the glucose 
metabolic phenotype of GSTP-null mice with that of WT mice.  Through the 
combination of glucose, insulin and C-peptide levels, glucose and pyruvate 
tolerance tests, high fat feeding, insulin signaling and secretion, we explored the 
changes to glucose production and utilization in GSTP-null mice, and found 
evidence for a novel role of GSTP in hepatic gluconeogenesis and insulin 
secretion to account for the glucose intolerance observed in this mouse model.  
RESULTS 
 
GSTP-null mice are glucose tolerant on normal chow diet.  
A key concern with gene knockout in animals is the possibility of compensatory 
changes in the expression of related or alternative genes. Since GSTs are 
inducible enzymes and most tissues express several GST isoforms, gene 
deletion of GSTP may be offset by increased expression of other GSTs. 
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However, studies using GSTP-null mice have confirmed lack of compensatory 
activation of other GSTs in major tissues such as lung, liver and heart. 
Kitteringham et al. performed a systematic comparison of the protein expression 
profiles of livers from GSTP-null and WT mice by proteomic techniques in an 
attempt to identify possible targets that explain the resistance of GSTP-null mice 
to acetaminophen-induced hepatotoxicity [55]. The authors demonstrated that 
deletion of mGstp1/2 was not compensated for by changes in the expression of 
other GST isoforms in the liver. Moreover, the authors found significant similarity 
in expression of approximately 200 proteins analyzed quantitatively in the liver 
supporting a highly selective nature of the phenotype of GSTP-null mice. Similar 
results have been reported in the hearts of GSTP-null mice [61]. Taken together, 
GSTP-null mice are a suitable model for investigating GSTP-specific effects. 
Although age-matched WT and GSTP-null male mice fed NC were similar 
in body weight, body composition (fat and lean mass), organ weights (including 
liver), fasting blood glucose, fasting plasma insulin, HOMA-IR, HOMA-β and 
other plasma measures (Fig. 14A-D; Table 1), the GSTP-null mice were 
significantly more glucose intolerant than WT mice (Fig. 14E-F) as determined by 
i.p. GTT. After 6 h of fasting, blood glucose levels were similar among the 
genotypes (indicated at 0 min) (Fig. 14E). Following glucose administration, 
GSTP-null mice exhibited severe hyperglycemia resulting in significantly greater 
AUC for glucose values from 0–120 min (Fig. 14F) compared with WT mice. This 
glucose-intolerant phenotype (~70-120% increase in glucose AUC) was repeated 
in multiple independent experiments to a similar extent in mice of several lines 
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and was observed in animals as early as 11 weeks of age. No differences were 
noted in metabolic profile between the genotypes (Fig. 14G-L). These data 
suggest a novel role for GSTP in glucose homeostasis and sets forth the 
possibility that altered GSTP predisposes to a pre-diabetic phenotype. 
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Table 2. Metabolic and plasma parameters of male WT and GSTP-null mice 
on normal chow diet. 
Values are mean ± SEM. Abbreviations: BW, body weight; EWAT, epididymal 
white adipose tissue; BAT, brown adipose tissue; TC, total cholesterol; HDL-C, 
high-density lipoprotein cholesterol; LDL-C. low-density lipoprotein cholesterol; 
TG, triglycerides; CK, creatine kinase; LDH, lactate dehydrogenase; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase. *P< 0.05, WT vs. Null by 
Student’s t-test or Mann-Whitney U test as appropriate.
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Table 2. Metabolic and plasma parameters of WT and GSTP-null mice  
 
Parameter Wild-Type (n) GSTP-null (n) 
   
Body composition (g)     
     Body weight 29.57 ± 0.36 (24) 29.36 ± 0.40 (23) 
     Lean mass 21.04 ± 0.32 (24) 21.34 ± 0.31 (23) 
     Fat mass 4.88 ± 0.14 (24) 4.56 ± 0.17 (23) 
Organ weights (% of 
BW) 
   
     Liver  4.33 ± 0.11 (16) 4.26 ± 0.09 (17) 
     EWAT  1.03 ± 0.09 (16) 1.24 ± 0.08 (17) 
     BAT     0.18 ± 0.02 (16)     0.28 ± 0.01 (17)*  
Plasma lipids (mg/dL)     
     TC 72.74 ± 1.90 (8) 73.64 ± 1.68 (18) 
     HDL-C 75.65 ± 2.70 (8) 74.97 ± 2.48 (18) 
     LDL-C 11.67 ± 0.54 (8) 12.84 ± 0.54 (18) 
     TG 44.42 ± 2.73 (8) 40.20 ± 2.12 (18) 
Plasma biochemistry     
     Albumin (g/dL) 2.579 ± 0.07 (8) 2.501 ± 0.03 (18) 
     Total protein (g/dL) 4.384 ± 0.08 (8) 4.285 ± 0.05 (18) 
     CK (U/L) 234.7 ± 57.31 (6) 190.8 ± 27.87 (15) 
     LDH (U/L) 205.6 ± 25.46 (6) 164.8 ± 10.89 (15) 
     ALT (U/L) 55.95 ± 6.99 (6) 35.49 ± 3.10 (15)* 





FIG. 14. GSTP-deletion in mice causes glucose intolerance.  
Glucose tolerance test (GTT), glycemic indices and indirect calorimetry 
measurements shown for WT and GSTP-null mice fed NC diet. (A) Fasting blood 
glucose; (B) Fasting plasma insulin; (C) HOMA-IR, and (D) HOMA-%β values in 
WT and GSTP-null mice. For GTT, (E) Blood glucose levels were measured 
before and after glucose bolus (1 mg/g lean mass, i.p.) in WT and GSTP-null 
mice, and (F) GTT area under the curve (AUC) values were calculated. Metabolic 
parameters were measured by indirect calorimetry in 12 week-old WT and 
GSTP-null mice using a PhenoMaster system: (G) oxygen consumption (VO2); 
(H) carbon dioxide production (VCO2); (I) respiratory exchange ratio (RER); (J, 
K) food and water intake; and, (L) total activity (movement). Values are mean ± 
SEM (n=5-50 per group). *P< 0.05, WT vs. GSTP-null by Student’s t-test or by 
Mann-Whitney U-test where appropriate. WT, open symbols or bars; GSTP-null, 
filled symbols or bars. 
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Short-term high fat diet does not further exacerbate obesity and glucose 
intolerance in GSTP-null mice.  
Obesity and T2D are each characterized by a strong interaction of genetics and 
environment. We investigated whether HFD aggravated metabolic derangements 
in GSTP-null mice compared with WT mice. To that end, weight gain, glucose 
tolerance and energy metabolism was examined in chow and HF-fed mice of 
both genotypes. Interestingly, following a short-term HFD feeding (60% kcal; 3.5 
weeks), weight gain was lower in GSTP-null mice compared with WT mice (Fig. 
15A). The differences persisted throughout the six-week study resulting in a 
small but statistically significant lesser cumulative weight gain in GSTP-null mice 
(6.38 ± 0.72 g in WT and 3.35 ± 0.68 g in GSTP-null mice, p<0.05, n=5-7 per 
group). However, this difference in weight gain was not accounted for by 
differences in HFD-induced changes in lean and fat mass or organ weights 
between genotypes (Fig. 15B-G). To investigate this point further, we subjected 
mice to indirect calorimetry to determine whether an increase in energy 
expenditure accounted for the surplus in energy intake that was not stored in 
adipose tissue of GSTP-null mice. However, both genotypes showed similar 
alterations in energy expenditure, caloric intake, locomotor movement and 
respiratory quotient following HFD (Fig. 16A-F). 
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FIG. 15.  Short-term diet-induced obesity in WT and GSTP-null mice. 
(A) Cumulative body weight (BW) of mice fed normal chow (NC) and high-fat diet 
(HF, 60% kcal fat) ad libitum for 6 weeks. Dual-energy X-ray absorptiometry 
(DEXA) analysis and glucose tolerance test (GTT) were performed at 3 or 3.5 
weeks of diet study, respectively (see arrows). (B) Lean and fat mass content as 
measured by DEXA. Inset: Representative DEXA images. (C) Fed and (D) 
Fasting (6h) blood glucose at weeks 2 and 3 of diet study measured by tail vein. 
(E-G) Organ to body weight ratios at the end of the diet study. Values are mean ± 
SEM (n = 5 per group). BW, body weight; EWAT, epididymal white adipose 
tissue; SubQ WAT, subcutaneous white adipose tissue; BAT, brown adipose 
tissue (interscapular); PVAT, perivascular adipose tissue. *P< 0.05, NC vs. HF by 
Mann-Whitney U test. NC, open symbols or bars; HF, filled symbols or grey bars.   
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Although short-term HFD feeding in GSTP-null mice increased adiposity, 
yet it did not increase GTT AUC over that of GSTP-null mice fed NC (Fig. 16G-
H).  Moreover, the GTT AUC of GSTP-null mice (regardless of diet) was similar 
to the GTT AUC of HFD-fed WT mice suggesting that the glucose intolerance 
effects of HFD in WT mice may be attributable solely to the downregulation of 
hepatic GSTP. Consistent with this hypothesis, although lacking GSTP, the 
hepatic protein levels of GSTA and GSTM in GSTP-null were similar to their 
levels in age-matched, NC-fed WT mice (Fig. 17A-E) indicating no compensatory 
upregulation in GSTP-null mice of these abundant GST isoforms. The total 
hepatic GST activity in GSTP-null mice was decreased by only about 24% 
(CDNB substrate; Fig. 17F) -- a decrease in GST activity that was similar 
(surprisingly) to the decreased hepatic GST activity measured in HFD-fed WT 
mice (see Fig. 8, Chapter III). Moreover, and despite the idea that fat 
accumulation in the liver causes hepatic IR [148, 149] and subsequently 
peripheral IR and glucose intolerance [150-152], levels of hepatic triglycerides 
and cholesterol were similar in WT and GSTP-null mice whether fed NC or HFD 
(Fig. 18). These data indicate that GSTP deficiency exerted a specific defect 
perhaps selectively hepatic that led to glucose intolerance. 
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FIG. 16. Short-term diet-induced obesity and glucose intolerance in WT and 
GSTP-null mice.  
Indirect calorimetry and glucose tolerance test (GTT) measurements are shown 
for WT and GSTP-null mice fed NC and HF diet. Metabolic parameters were 
measured by indirect calorimetry in 12 week-old WT and GSTP-null mice using a 
PhenoMaster system: (A) oxygen consumption (VO2); (B) carbon dioxide 
production (VCO2); (C) respiratory exchange ratio (RER); (D) total activity 
(movement); and (E, F) food and water intake. (G) For GTT, mice were fasted for 
6 h and injected intraperitoneally with glucose bolus (1 mg/g of lean mass). Blood 
glucose was measured by tail vein, and (H) the area under the curve (AUC) was 
calculated. Values are mean ± SEM (n = 5-7 per group). HOMA-IR and HOMA-
%β, homeostasis model assessment-estimated insulin resistance and β-cell 
function indices. *P< 0.05, NC vs. HF or WT vs Null by Mann-Whitney U test and 
One-way ANOVA analysis as appropriate
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Fig. 17. Glutathione S-transferases expression and activity in liver of WT 
and GSTP-null mice.  
(A) Gsta4, Gstm4.1, and Gstp1 mRNA expression (normalized to Rplp0) in liver 
of WT and GSTP-null mice fed NC (n=6-8 per group). (B) Representative 
Western blots of liver lysates for GSTA, GSTM and GSTP and respective (C) 
densitometric analyses (n=3 per group). (D, E)  Liver sections from WT and 
GSTP-null mice stained with anti-GSTP antibody. (F) Hepatic GST activity 
measured with 1-chloro-dinitrobenzene (CDNB) as substrate (n=10-11 per 
group). Values are mean ± SEM. *P< 0.05, by Mann-Whitney U test. NC, open 
symbols or bars; HF, filled symbols or bars. 
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Fig. 18.  Short-term diet-induced obesity and hepatic lipids in WT and 
GSTP-null mice.  
Measurements were made in WT and GSTP-null mice fed normal chow (NC) and 
high-fat diet (HF, 60% kcal fat) ad libitum for 6 weeks. (A) Total triglycerides (TG) 
and (B) cholesterol (TC) were measured on livers collected at the end of the diet 
study. Values are mean ± SEM (WT n = 5 and GSTP-null n=7 animals per 
group). *P< 0.05, NC vs. HF and WT vs. GSTP-null by Mann-Whitney U test. NC, 
open bars; HF, grey bars. 
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These characteristics of GSTP-null mice are reminiscent of the natural 
history of T2D in certain populations which develop diabetic complications 
independent of obesity and carry polymorphic GSTP variants. Thus, GSTP-null 
mice represent a relevant animal model for gaining insights into 
pathophysiological mechanisms operative in human T2D. 
GSTP-null mice exhibit increased hepatic phospho-JNK abundance and 
protein-acrolein adduct formation. 
Because GSTP-null mice have both diminished acrolein metabolism and 
increased JNK activation under basal and stressful conditions [59, 107], we 
measured both protein-acrolein adducts and JNK phosphorylation status in the 
major glucose disposal organs (liver, skeletal muscle and adipose). Under basal 
conditions, a single protein-acrolein adduct band (i.e., Mr 90 kDa, +1.3 fold; 
p<0.05; Fig. 19A-B) was statistically increased in liver of NC-fed GSTP-null and 
WT mice. No differences in adduct levels were observed in skeletal muscle and 
adipose of GSTP-null and WT mice fed either NC or HFD (Fig 19C-F). High fat 
feeding did not have an additive effect in increasing protein-acrolein adducts in 
GSTP-null mice compared with WT mice (Fig. 20 and 21). 
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Fig. 19. Protein-acrolein adducts in WT and GSTP-null mice.  
 
Representative Western blots of protein-acrolein adduct bands in (A) liver, (C) 
gastrocnemius skeletal muscle, and (E) epididymal white adipose tissue and 
respective (B, D, F) densitometric analyses. Values are mean ± SEM (n=6 per 
group). *P< 0.05, NC vs. HF by Mann-Whitney U-test. NC, open bars; GSTP-null, 
filled bars.  
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Fig 20. Protein-acrolein adducts in normal chow and high-fat diet fed GSTP-
null mice.  
Representative Western blots of protein-acrolein adduct bands in liver of (A) 
GSTP-null mice fed NC and HFD; (C) WT and GSTP-null mice fed HFD, and 
respective (B, D) densitometric analyses. Values are mean ± SEM (n=5-6 per 








Fig 21. Protein-acrolein adducts in normal chow and high-fat diet fed WT 
mice. 
Representative Western blots of protein-acrolein adduct bands in (A) 
gastrocnemius skeletal muscle, and (C) epididymal adipose tissue and 
respective (B, D) densitometric analyses. Values are mean ± SEM (n=5 per 
group). *P< 0.05, NC vs. HF by Mann-Whitney U-test.  
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Because acrolein (and other unsaturated aldehydes) can induce protein-
aldehyde adducts and endoplasmic reticulum stress (ER-stress; [99]) that can 
activate JNK [6, 140], the hepatic levels of XBP-1 splicing and known ER-stress 
markers, HERP and GRP78 [153], were measured. The levels of these ER stress 
markers were similar in livers of GSTP-null and WT mice (Fig. 22).  However, as 
observed in WT mice fed HFD, hepatic abundance of phospho-p54 JNK (but not 
phospho-p46) was greater in GSTP-null than in WT mice (Fig. 23A-C). In 
adipose and skeletal muscle, however, the levels of phospho-JNK (p54, p46) 
were similar in GSTP-null and WT mice (Fig. 23D-G). Furthermore, hepatic 
phospho-JNK abundance was increased to a similar degree in HFD-GSTP-null 
mice compared with HFD-WT mice. Collectively, these data show GSTP 
deficiency had selective effects on hepatic accumulation of protein-acrolein 
adducts and JNK (p54) activation in the absence of ER stress – effects not 
observed in the other major insulin-sensitive organs.  
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Fig. 22. Hepatic ER stress markers in WT and GSTP-null mice.   
Xbp-1 splicing was assessed by RT-PCR, and Herp and Grp78 mRNA 
expression (normalized to Rplp0) in livers of 6 h fasted WT and GSTP-null mice 
was assessed. Values are mean ± SEM (n=6 animals per group). *P< 0.05, WT 
vs. GSTP-null by Mann-Whitney U-test. WT, open bars; GSTP-null, filled bars. 
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FIG. 23. JNK phosphorylation in WT and GSTP-null mice on NC diet.  
 
Representative Western blots for phospho-JNK (Thr183/Tyr185) and total JNK 
(p54/p46) in (A) liver, (D) gastrocnemius skeletal muscle, and (E) epididymal 
white adipose tissue and respective (B, C, F, G) densitometric analyses. Values 
are mean ± SEM (n=6 per group). *P< 0.05, WT vs. null by Mann-Whitney U-test. 
NC, open bars; GSTP-null, filled bars.  
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FIG. 24. JNK phosphorylation in WT and GSTP-null mice fed high-fat diet.  
 
Representative Western blots for phospho-JNK (Thr183/Tyr185) and total JNK 
(p54/p46) in (A) liver of GSTP-null mice fed HF-diet; and (D) epididymal white 
adipose tissue from NC- and HF-fed WT and GSTP-null mice and respective 
densitometric analyses (B, C, E, F). Values are mean ± SEM (n=5 per group). 
*P< 0.05, NC vs. HF for each genotype by Mann-Whitney U-test.  
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Figure 24. JNK phosphorylation in GSTP-null mice on HFD 
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Insulin sensitivity and increased gluconeogenesis in GSTP-null mice. 
 JNK activation impairs insulin signaling in diabetes [139], but how hepatic JNK 
activation in GSTP-null mice increases glucose intolerance is unclear.  To assess 
insulin signaling in GSTP-null mice, glucose disposal and Akt phosphorylation 
was measured after insulin injection. The fall in glycemia at 15 min after insulin 
injection was similar in both genotypes, suggesting insulin sensitivity was 
preserved in GSTP-null mice (data not shown). Consistent with this 
interpretation, insulin stimulated robust Akt phosphorylation (pSer473-Akt) in liver, 
skeletal muscle and adipose tissue with no differences between GSTP-null and 
WT mice (Fig. 25). Because the level of blood glucose (as in a GTT) is a 
consequence of the opposing forces of glucose uptake and glucose output, we 
tested whether GSTP-null mice had increased hepatic glucose output. To test 
this, we conducted a pyruvate tolerance test (PTT). Mice were challenged with 
the gluconeogenic precursor, pyruvate and hepatic glucose output (HGP) was 
estimated. As shown in Fig. 26A, following pyruvate injection, GSTP-null mice 
exhibited enhanced blood glucose excursion during the first 30 min (Fig. 26B), 
suggesting a higher gluconeogenic potential in the absence of GSTP. These 
differences persisted throughout the 120 mins of the PTT (Fig. 26C) and resulted 




Fig. 25. Insulin signaling in WT and GSTP-null mice.  
(A-F) Total Akt and phospho-Akt (Ser473) following saline or insulin (1.5U/kg 
lean mass, ip) bolus in NC-fed WT and GSTP-null mice after a 6 h fast. 
Representative blots are shown for liver, gastrocnemius skeletal muscle and 
epididymal adipose tissue (top, middle and lower panels respectively) along with 
respective (B, D, F) densitometric analyses. Bar values = mean ± SEM from 3 
independent experiments (n = 6 animals per group). *P< 0.05, WT vs. GSTP-null 
by Mann-Whitney U-test.  
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FIG. 26. GSTP-null mice have increased gluconeogenesis.  
Pyruvate tolerance test (PTT) measurements are shown. (A) Blood glucose 
levels were measured before and after pyruvate bolus (2 mg/g lean mass, i.p.) in 
WT and GSTP-null mice (WT n=7; GSTP-null n=15). (B) Delta 30 min blood 
glucose values relative to baseline for vehicle and JNKI-treated GSTP-null mice 
(also referred to as the “glucose appearance rate”). (C) Blood glucose values 
percent of baseline at 120 min of the PTT for each genotype; (D) PTT area under 
the curve (AUC) values. (E) GTT AUC was plotted relative to PTT AUC for 
GSTP-null mice. Values are mean ± SEM. *P< 0.05, WT vs. GSTP-null by Mann-
Whitney U-test. WT, open symbols; GSTP-null, filled symbols. 
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Additionally, the PTT AUC was significantly correlated with the GTT AUC (r2=0.3, 
p=0.02) in GSTP-null mice (Fig. 14E), further supporting the idea that hepatic 
glucose output was contributing to overall elevated glucose intolerance in GSTP-
null mice.  
Glucose homeostasis in rodents, as in humans, is a function of the rate of 
insulin release in response to glycemia and insulin sensitivity of peripheral 
organs. The balance between these two factors determines the overall 
physiological tolerance to glucose and the capacity to sustain glucose 
homeostasis within the normal physiological range. Because GSTP-null mice 
exhibited robust Akt phosphorylation in peripheral tissues, we inferred that 
impaired glucose tolerance (and increased gluconeogenesis) in GSTP-null mice 
is not likely explained by insulin resistance.  Therefore, we tested whether 
glucose-stimulated insulin secretion (GSIS) is altered in GSTP-null mice. 
GSTP-null mice exhibit decreased glucose-stimulated insulin secretion 
(GSIS).  
The peak insulin secretion and action is reported in the literature to be within 
~25-30 min following glucose bolus administration in mice. The half-life of insulin 
in mice is ~10-15 min and that of the pro-insulin cleavage product, C-peptide is 
~30 min. Endogenous measurement of plasma C-peptide is a clinically validated 
assessment of β-cell function.  We measured glucose-stimulated plasma insulin 
and C-peptide levels at 20 and 30 min post glucose challenge in independent 
cohorts of age-matched WT and GSTP-null mice. Fasting plasma glucose and C-
peptide levels were similar in WT and GSTP-null mice. In contrast, plasma insulin 
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levels were decreased by ∼10-fold in GSTP-null mice compared with WT mice at 
20 min post glucose bolus, yet the difference was normalized at 30 min post 
glucose injection (Fig. 27A). C-peptide levels also were decreased in GSTP-null 
versus WT mice (Fig. 27B), consistent with the decreased insulin secretion. In 
contrast, the C-peptide/insulin ratio, which reflects insulin clearance, was 
unaltered in GSTP-null mice compared with WT mice (Fig. 27E). Together, these 
findings indicate that the hyperglycemia of GSTP-null mice results, at least in 
part from insulin hyposecretion rather than from differences in insulin 
resistance or clearance, which were unaltered in GSTP-null mice.  
GSTP-null mice exhibit decreased pyruvate-stimulated insulin secretion 
(PSIS).  
Next, we asked whether altered insulin responses could account for the 
divergent PTT curves of WT and GSTP-null mice, which would link insulin 
secretion, rather than hepatic insulin resistance to increased gluconeogenesis in 
GSTP-null mice. The effect of injection of a gluconeogenic substrate on the 
hormonal response was determined in GSTP-null mice. Plasma insulin 
concentrations were measured from blood samples collected before and after 
pyruvate bolus at precise time points (20 and 60 min respectively) based on 
literature reports of PSIS studies in mice. GSTP-null mice did not display altered 
plasma insulin and C-peptide levels in the plasma sample taken 20 min after the 
pyruvate load (Fig. 27C-D); however, compared with WT mice, GSTP-null mice 
exhibited significantly decreased plasma insulin levels at 60 min after the 
pyruvate bolus (Fig. 27C-D).  Similar to GSIS, the C-peptide/insulin ratio was 
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unaltered in GSTP-null mice compared with WT mice (Fig. 27F). These data 
suggest that decreased insulin secretion could account for the increased 
gluconeogenesis (by PTT) of the GSTP-null mice. 
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FIG. 27. Glucose and pyruvate-stimulated insulin and C-peptide secretion 
in WT and GSTP-null mice.  
For detailed experimental design, see Fig. 3. (A) Plasma insulin and ( E) C-
peptide values are shown for plasma samples collected at 20 and 30 min post 
glucose injection. (D) Plasma insulin and (E) C-peptide values are shown for 
plasma samples collected at 20 and 60 min post pyruvate injection. (C) C-peptide 
to insulin ratio in plasma samples collected at 30 min post glucose injection; (F) 
C-peptide to insulin ratio in plasma samples collected at 60 min post pyruvate 
injection; Values are means ± SEM, n=10-12 animals per group, *P< 0.05, WT 
vs. GSTP-null by Student’s t-test or by Mann-Whitney U-test where appropriate. 
WT, open bars; GSTP-null, filled bars. 
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Hepatic gluconeogenesis and inflammation.  
Because hepatic glucose output is a function of gluconeogenesis and the 
abundance of its rate limiting enzymes, phosphoenolpyruvate carboxykinase 
(PEPCK) and glucose-6-phosphatase (G6Pase) [153], we examined hepatic 
mRNA levels of Pepck and G6pc. Surprisingly, we found no differences in 
hepatic mRNA levels of Pepck and G6pc between 6 h fasted GSTP-null and WT 
mice (Fig. 28A). Because activated JNK is linked with inflammatory signaling, 
hepatic inflammatory genes were measured. Hepatic mRNA levels of Mip-1alpha 
(~6 fold) but not of Il-6, Mcp-1 and Il-1beta were significantly greater in GSTP-null 
compared with WT mice (Fig. 28B). Significant relationships between hepatic 
gluconeogenesis and inflammation markers were revealed in GSTP-null but not 
in WT mice using Spearman’s rank correlation (Fig. 28D-E). For example, the 
following pairs of gene mRNAs were highly correlated: 1) Mcp1 and Pepck 
(p=0.05); 2) Mcp-1 and Il-1beta (p=0.00); and, 3) Il-1beta and Pepck (p=0.02) 
(Table 3). Although the signaling relationship between activated JNK, 
gluconeogenesis and cytokines in the liver is complicated, these data likely 
support a coordinating role of JNK in the glucose intolerance of GSTP-null mice. 
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FIG. 28. Gluconeogenic and inflammatory mRNA markers in WT and GSTP-
null mice. 
(A) Hepatic gluconeogenic markers; and inflammatory markers mRNA 
expression in (B) liver and (C) epididymal adipose tissue  (normalized to Rppo) 
of NC-fed WT and GSTP-null mice; (D, E) Spearman’s correlation analyses 
between hepatic inflammatory and gluconeogenic markers in NC-fed WT and 
GSTP-null mice are shown. Colors of spheres represent strength of correlation, 
with brown representing a positive association and blue representing a negative 
association. In each case, dark colors show a high degree of association. Values 
are means ± SEM (n=6-8 animals per group). *P< 0.05, WT vs. GSTP-null by 
Mann-Whitney U-test. WT, open bars; GSTP-null, filled bars. 
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Table 3. Spearman’s correlation co-efficients of gluconeogenic and 
inflammatory markers in GSTP-null mice 
Spearman’s Rank Correlation Coefficients of hepatic gluconeogenic and 







r P r P 
WT Null  WT Null  
Mcp-1 -0.429 -0.886 N.S. 0.771 -0.486 <0.05 
Mip-1alpha -0.6 -0.771 N.S. 0.771 -0.029 N.S. 
Il-1beta -0.429 -0.087 N.S. 0.771 -0.667 <0.05 
Il-6 0.2 0.371 N.S. 0.771 0.371 N.S. 
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JNK and hepatic gluconeogenesis.  
Thus, to test the hypothesis that activated JNK was promoting glucose 
intolerance (via increased gluconeogenesis) in GSTP-null mice, we inhibited JNK 
phosphorylation in vivo using SP600125, a competitive inhibitor of ATP-binding 
site in JNK. Following 7 consecutive days of treatment, JNK inhibitor had no 
effect on fasting blood glucose and body weight indicating no untoward toxicity 
(Fig. 29A and t = 0 of Fig. 17B). Compared with vehicle, SP600125 suppressed 
glucose production from pyruvate in GSTP-null mice (PTT; Fig. 29B-E). The PTT 
AUC was reduced by 45±7% (p<0.05, n=11; Fig. 29E) in SP600125-treated mice 
compared with vehicle-treated littermate controls. This percentage decrease was 
calculated taking into account the GSTP-attributable effect on PTTAUC, as 
known from previous PTT experiments in WT and GSTP-null mice. To test what 
hepatic targets were altered by JNK inhibition, we re-assessed hepatic mRNA 
levels and their inter-relationships using Spearman’s Rank Correlation 
Coefficients.  Surprisingly, we found no differences between hepatic mRNA 
levels (including for Mip-1alpha) between JNK inhibitor and saline-treated mice 
(Fig. 30A-B), however, the SP600125 treatment significantly altered the 
correlations between hepatic Mcp-1 and G6pc mRNAs and Mcp-1 and Pepck 
mRNAs (Fig. 30C-D; Table 4) indicating that JNK activation was coordinating the 
basal levels of these mRNAs in GSTP-null mice. These data support the 
contention that JNK activation is, at least in part, responsible for the increased 
hepatic gluconeogenesis (perhaps via regulation of inflammatory and 
gluconeogenic genes) in GSTP-null mice
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FIG. 29. Increased gluconeogenesis was reversed by JNK inhibitor in 
GSTP-null mice.  
Pyruvate tolerance test (PTT) measurements are shown for vehicle and JNK 
inhibitor (JNKI; i.p. 5 mg/kg, 7 days, once daily)-treated GSTP-null mice (n=11 
per group). For experimental design of inhibitor study, see Fig. 3, Chapter II. (A) 
Body weights of mice are shown for the 7 consecutive days of injection. (B) 
Blood glucose levels were measured before and after pyruvate bolus (2 mg/g 
lean mass, i.p.). (C) Delta 30 min blood glucose values relative to baseline for 
vehicle and JNKI-treated GSTP-null mice (also referred to as the “glucose 
appearance rate”). (D) Blood glucose values at 120 min of PTT expressed as 
percent of baseline values for each treatment group. (E) PTT area under the 
curve (AUC) values.  Values are mean ± SEM. *P< 0.05, Vehicle vs JNKI by 
Mann-Whitney U-test. Vehicle, open symbols; JNKI, filled symbols or grey bars. 
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Fig. 30. Hepatic gluconeogenic and inflammatory mRNA markers in GSTP-
null mice treated with vehicle or JNK inhibitor.  
(A) Hepatic gluconeogenic markers and (B) inflammatory markers mRNA 
expression (normalized to Rppo) in vehicle or JNK inhibitor (JNKI, SP600125, 5 
mg/day/kg body weight, 7 days)-treated GSTP-null mice; (C, D) Spearman’s 
correlation analyses between hepatic inflammatory and gluconeogenic markers 
are shown. Colors of spheres represent strength of correlation, with brown 
representing a positive association and blue representing a negative association. 
In each case, dark colors show a high degree of association. Values are means ± 
SEM (n=6-8 animals per group). *P< 0.05, Vehicle vs. JNKI by Mann-Whitney U-
test. Vehicle, open bars; JNKI, filled bars. 
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Figure 30. Effect of JNK inhibitor on gluconeogenic and inflammatory 




Table 4. Effect of JNK inhibitor on Spearman's correlation co-efficients of 
gluconeogenic and inflammatory markers in GSTP-null mice 
 
Spearman’s Rank Correlation Coefficients of hepatic gluconeogenic and 
inflammatory marker mRNAs in GSTP-null mice fed normal chow diet and 






r P r P 
Vehicle JNKI  Vehicle JNKI  
Mcp-1 -0.867 -0.105 <0.05 -0.491 0.42 <0.05 
Mip-1alpha -0.6 -0.280 N.S. 0.164 0.098 N.S. 
Il-1beta -0.612 0.063 N.S. -0.042 0.308 N.S. 





It is appreciated that both β-cell dysfunction and insulin resistance are early and 
necessary events in the development and progression of glucose intolerance to 
type 2 diabetes [154]. The novel finding of this study is the role of hepatic GSTP 
in glucose homeostasis via its effect on hepatic gluconeogenesis and insulin 
secretion. GSTP-null mice fed normal chow diet were glucose intolerant. 
Furthermore, glucose intolerance in GSTP-null mice is unchanged by HFD 
feeding and appears to be a function of JNK activity. We confirmed the role of 
JNK (i.e., reversed by SP600125, a JNK inhibitor) in glucose intolerance, and 
that JNK-dependent glucose output results from increased hepatic 
gluconeogenesis. Collectively, we conclude that downregulation of hepatic GSTP 
(whether by HFD or genetic manipulation or gene polymorphism) selectively 
increases JNK activation that, in turn, alters hepatic signaling to promote 
gluconeogenesis and intolerance (see Schematic, Fig. 19).  The GSTP-null 
genotype thus recapitulates the early deleterious events leading from diet-
induced obesity to diabetes. 
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FIG. 31. . Schematic showing how high fat diet or GSTP-null genotype 
affects glucose intolerance via liver-specific JNK activation in mice.  
Effects of high fat (HF) diet in wild-type (WT) are shown with blue arrows. Effects 
of the GSTP-deficient genotype (GSTP-null) occurring independently of obesity 
are shown with red arrows. HF diet results in glucose intolerance in WT mice, 
typical of this commonly utilized model of diet-induced obesity [127]. In the liver, 
HF feeding decreases GSTP protein and total GST activity concomitant with 
increased protein-acrolein adduct and phospho-JNK abundance, in agreement 
with the known functions of GSTP [36, 102]. Hepatic phospho-p54 JNK positively 
correlates with glucose intolerance in HF-fed mice. Because GSTP is an in vivo 
JNK inhibitor [107], decreased hepatic GSTP could augment JNK activation 
following early diet-induced obesity. Consistent with this, GSTP-null genotype 
elicits similar metabolic derangements. GSTP-null mice exhibit positively 
correlated glucose and pyruvate-intolerance on normal chow diet, suggesting 
that increased hepatic glucose contributes to glucose intolerance. Livers of 
GSTP-null mice show increased protein-acrolein adduct and phospho-JNK 
abundance, thereby recapitulating the HF-induced sequelae in WT mice. 
Treatment with JNK inhibitor, SP600125, alleviates hepatic glucose output in 
GSTP-null mice, thus illustrating a novel role for GSTP in glucose tolerance via 
JNK regulation.   
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In the current study, we provide evidence that hepatic JNK activation 
contributes to the early derangements in glucose control. First, we show that 
phospho-JNK abundance (p54 but not p46) is selectively increased in the livers 
of GSTP-null mice on normal chow, like was observed in obese WT livers. 
Second, increased hepatic glucose output was associated with a pyruvate bolus 
in GSTP-null on normal chow diet.  Third, the JNK inhibitor, SP600125, 
significantly corrected glucose intolerance associated with a pyruvate bolus.  This 
experiment shows that JNK activation augments hepatic gluconeogenesis (i.e., 
pyruvate fuels reverse glycolysis in liver [155]) and that this can occur in the 
absence of HFD, obesity or a genetic model of obesity and IR (e.g., db/db mice).  
Thus, the absence of GSTP is sufficient to promote JNK activation [107], and 
hepatic gluconeogenesis, a known mediator of enhanced glycemia in T2D [156]. 
Although augmented JNK activation in peripheral tissues is known to mediate 
glucose intolerance and IR [139], these models do not address the earliest 
events that precede established systemic insulin resistance.  In fact, our study 
shows that insulin signaling is intact and robust in liver, skeletal muscle and 
adipose of GSTP-null mice despite hepatic JNK activation showing that 
increased hepatic glucose output precedes hepatic insulin resistance per se.  
Although we used whole body GSTP-null mice, these mice are identical to WT 
mice in body composition, metabolism, activity, fasting blood glucose and insulin 
and food and water intake (see Fig. 4 and Table 1) indicating a selective effect of 
GSTP-deletion on hepatic glucose output likely important in glucose excursions 
after feeding. Moreover, despite using whole body GSTP-deficient mice, we 
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observed a continuum of glucose intolerance (see Fig. 4E) that likely reflects a 
currently unidentified stress factor in these mice.  
A potential factor known to induce JNK activation is the accumulation of 
aldehyde-modified proteins (carbonylated proteins), and protein-aldehyde 
adducts are considered determinants of inflammation and IR [30, 46].  Because 
GSTP activity selectively conjugates GSH with acrolein [52], we measured and 
found increases in protein-acrolein adducts in liver (but not in skeletal muscle nor 
in adipose) of both short-term HFD-fed WT and NC-fed GSTP-null mice 
compared with NC-fed WT mice. Although acrolein-modified and unfolded 
proteins can trigger ER stress and the unfolded protein response (UPR) that can 
initiate JNK activation [98], we did not find obvious evidence of ER stress-
induced UPR in GSTP-null mice. Interestingly, a general pattern of protein-
acrolein adducts (5 prominent Mr bands: 125, 90, 77, 75, 27 kDa) appears in both 
HFD-fed WT and GSTP-null mice and some of these bands are significantly 
increased although not the same ones in both models. While the role of these 
adducts in JNK activation is unclear, the accumulation of these adducts reflects 
diminished acrolein detoxification capacity that is consistent with the decreased 
overall GSTP abundance and GST activity (using CDNB as substrate), which is 
surprisingly similar (approx. 25% loss) in livers of both HFD-fed WT and GSTP-
null mice. The prospect of protein-acrolein adducts as perpetrators of hepatic 
JNK activation and glucose intolerance remains to be investigated.  
Hepatic JNK activation has been shown to play a pivotal role in causing IR 
and glucose intolerance in diabetic animal models [126].  Although we did not 
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definitely reveal a single mechanism how JNK (or if it was JNK1 or JNK2) 
augments hepatic gluconeogenesis, we did reveal potential relationships 
between rate limiting gluconeogenic enzymes and inflammatory mediators using 
Spearman’s Rank Correlation Coefficient analyses in glucose intolerant GSTP-
null mice. Supporting this approach, cytokines, IL-1β and IL-10, exert influence 
over hepatocyte PEPCK mRNA, protein and enzyme activity demonstrating an 
interaction between Kupffer cells and hepatocyte gluconeogenesis [157]. 
Similarly, hepatic and circulating chemokines such as MIP-1alpha and MCP-1 
are potential candidates linking obesity with IR [158, 159] in humans and mice. In 
our present study, JNK inhibitor significantly disrupted the relationship between 
hepatic Mcp-1 and G6pc mRNAs and Mcp-1 and Pepck mRNAs. We did not see 
a change in Mip-1alpha mRNA after SP600125, which suggests that MIP-1α lies 
upstream of JNK rather than as a consequence of JNK activity. Further analyses 
of specific signaling (e.g., cell type, JNK isoform) events and targets of JNK 
(independent of insulin signaling) are required to define the complicated role of 
activated JNK in regulation of hepatic gluconeogenesis as an early event in diet-
induced glucose intolerance.  
In summary, these are the first studies to demonstrate that deletion of the 
murine Gstp1/2 genes results in glucose intolerance, decreased insulin release 
and increased hepatic glucose production independently of obesity. These 
findings in a mouse model of GSTP-deficiency recapitulate the early deleterious 
events observed following HFD feeding in WT mice. Glucose intolerance in 
GSTP-null mice is manifest in the absence of defects in insulin signaling in major 
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glucose disposal organs – skeletal muscle, adipose and liver and may be 
ascribed, at least in part, to an inability to raise plasma insulin levels in response 
to hyperglycemia. JNK appears to orchestrate relationships between hepatic 
cytokine and rate-limiting gluconeogenic enzymes that predispose the liver of 
GSTP-null mice to increase glucose output.  These data predict that variation(s) 
in GSTP abundance or function may modulate diabetes susceptibility and/or 





CONCLUSIONS AND FUTURE DIRECTIONS 
 
This project was designed to achieve new understanding of how the 
glutathione-S-transferase pi isozyme (GSTP) contributes to glucose 
homeostasis. In Chapter I, we put forth the hypothesis that GSTP is 
downregulated in obesity and diabetes and is a key modulator of glucose 
tolerance via its role (s) in aldehyde metabolism and JNK regulation (Figure 
1). We used two different animal models to address the hypothesis. First, the 
effect of obesity on GSTP was assessed by high-fat diet (HFD) feeding in 
C57BL/6J mice (Chapter III), as it remains the most well accepted model for 
studying impaired glucose tolerance and early type 2 diabetes [127]. Second, the 
in vivo effect of GSTP deficiency on glucose homeostasis was investigated by 
using whole-body GSTP-deficient (GSTP-null) mice (Chapter IV). Through the 
work in this thesis, we have 1) elucidated the effect of diet-induced obesity on 
GSTP expression and function in insulin-responsive tissues as it relates to the 
development of glucose intolerance and insulin resistance, 2) identified a glucose 
intolerance phenotype in GSTP-null mice, 3) uncovered a potentially novel 
pathway of hepatic gluconeogenesis that likely operates via JNK activation and 
inflammation in GSTP-null mice and 4) illustrated that glucose-stimulated insulin 
secretion is decreased in GSTP-null mice. We propose that hepatic GSTP
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contributes to glucose homeostasis in mammals by modulating hepatic glucose 
production; reduced hepatic expression of GSTP might be a critical instigator of 
hyperglycemia in type 2 diabetes, thus adding a new player to our evolving 
understanding of this physiology. 
We assessed the impact of HFD feeding on GSTP abundance, protein-
acrolein adducts and JNK phosphorylation in insulin-sensitive tissues. As 
discussed in Chapter III, HFD induced significant weight gain and adiposity as 
early as 3.5 weeks. Glucose tolerance test showed marked glucose intolerance 
in HF-fed animals. Systemic metabolic parameters were significantly altered by 
HF feeding as expected. HF feeding induced marked elevations in fasting plasma 
insulin and HOMA-IR and HOMA-β indices, consistent with obesity-induced 
insulin resistance. In examining the relationship between these early metabolic 
derangements and GSTs, abundance of GSTP was greatly diminished 
selectively in the livers of diet-induced and genetic mouse models of glucose 
intolerance and insulin resistance. Such tissue-specific dysregulation has been 
documented for other GST isozymes in human and animal studies of obesity, 
diabetes and NAFLD [45, 135]. As functional indices of decreased GSTP 
abundance, hepatic protein-acrolein adducts and phospho-JNK abundance (p54 
but not p46) were significantly elevated in obese mice. Collectively, we conclude 
that downregulation of hepatic GSTP selectively increases JNK activation and 
induces deficits in aldehyde detoxification that, in turn affects pathways of 
glucose storage and/or production to promote glucose intolerance. Dietary 
nutrients or phytochemicals have been reported to restore GSTP protein 
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expression and have been studied in cancer. For instance, phytoestrogens, 
phenethyl isothiocyanate, a phytochemical found in large amounts in cruciferous 
vegetables, green tea polyphenols and lycopene have been studied. It is 
interesting to postulate that using such compounds to restore hepatic GSTP 
levels and functionality in obesity may have beneficial effects on glucose 
handling in mouse models. Furthermore, in vitro and in vivo studies are needed 
to understand the mechanisms that underlie GSTP downregulation following 
HFD feeding. Multiple mechanisms are plausible as outlined in Chapter I (such 
as transcriptional, hormonal, epigenetics, microRNA).  
To delineate the role of GSTP in glucose metabolism, we used GSTP-null 
mice. Compared with WT mice, GSTP-null mice are identical in body 
composition; metabolism, fasting glycemia and insulin and food and water intake 
(see Fig. 14 and Table 2). However, GSTP-null mice were glucose and pyruvate 
intolerant on normal chow (NC) diet, indicating a selective effect of GSTP-
deletion on hepatic glucose output likely important in glucose excursions after 
feeding. Furthermore, GSTP-null mice exhibited decreased glucose-stimulated 
insulin secretion at an early time point of 20 min post glucose injection. JNK 
activation, which is known to impair both insulin signaling and insulin secretion in 
diabetes, was an important physiological correlate of glucose intolerance in both 
WT-HFD and in GSTP-null mice. First, we showed that phospho-JNK abundance 
was selectively increased in the livers of GSTP-null mice on normal chow, similar 
to that observed in obese WT livers. Second, treatment with JNK inhibitor, 
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SP600125, significantly attenuated hepatic glucose output in GSTP-null mice 
confirming the role of JNK in GSTP-mediated glucose regulation.  
A global gene knockout approach, as embodied by GSTP-null mice, 
allows us to test GSTP requirement but not GSTP sufficiency while also not 
identifying the tissue that contributes to the phenotype. Future studies of 
adenoviral vector-mediated liver-specific GSTP re-expression in GSTP-knockout 
mice that improves the glucose intolerance phenotype would further corroborate 
our current results.  
We found increases in hepatic protein-acrolein adduct in both short-term 
HFD-fed WT and NC-fed GSTP-null mice compared with NC-fed WT mice. The 
accumulation of acrolein adducts indicate deficits in acrolein detoxification 
capacity that was consistent with the observations of decreased overall GST 
activity in livers of both HFD-fed WT and GSTP-null mice. Measurement of free 
acrolein in tissues remains a tricky endeavor, due to acrolein being highly volatile 
and reactive. Accurate detection and quantification of endogenous acrolein relies 
on complicated methods using carbonyl derivatizing reagents [61]. Additional 
studies are needed to quantify HFD-induced acrolein generation in rodent livers. 
Acrolein-modified proteins can trigger ER stress and the unfolded protein 
response (UPR) that can initiate JNK activation (10). As indicators of ER-stress 
we measured Xbp-1 splicing, Herp and Grp78 mRNA and found that they were 
no different in the WT and GSTP-null livers. Future studies are warranted to 




Hepatic JNK activation has been shown to play a causal role in IR and 
glucose intolerance in diabetic animal models [126]. Our study shows that insulin 
signaling is intact and robust in peripheral tissues of GSTP-null mice despite 
hepatic JNK activation suggesting that increased gluconeogenesis is 
independent of hepatic IR in the GSTP-null model of glucose intolerance. 
Although JNK inhibitor data revealed potential relationships between rate limiting 
gluconeogenic enzymes and inflammatory mediators using Spearman’s Rank 
Correlation Coefficient analyses, further studies are essential to define the 
mechanism how JNK (and JNK1 or JNK2) augments hepatic gluconeogenesis in 
GSTP-deficient mice. To identify potential factors that regulate gluconeogenesis 
in GSTP-null livers, and to determine the site and mechanism of their actions as 
well as substrate utilization and flux through the pathway, future studies could 
utilize isolated perfused liver preparations that would provide a milieu similar to 
that in vivo while retaining the advantages of a system operating in vitro.  
In the present study, we assessed and found no differences in mRNA for 
Pepck and G6pc. Increased hepatic gluconeogenesis is often ascribed to 
transcriptional regulation of Pepck and G6pc [160] [161] [162] [163]. Yet, it has 
been demonstrated that the control they exert over gluconeogenic flux is 
relatively weak [164-167]. It has recently been reported that hepatic expression 
of Pepck and G6pc mRNA was not related to fasting hyperglycemia in humans 
and in rodent models of T2D [168]. The authors revealed a strong association 
between pyruvate carboxylase protein expression and glycemia in humans 
[169]. Pyruvate carboxylase is allosterically activated by acetyl-CoA [170]. 
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Enhanced expression of pyruvate carboxylase has been reported in rodent 
models of type 1 diabetes [171, 172] and in obese Zucker Diabetic Fatty (ZDF) 
rats [173]. Thus, future studies could examine effects of GSTP deletion on such 
additional regulatory mechanisms of the gluconeogenic pathway.  
Although a PTT can be useful in cases of severe alterations in hepatic 
gluconeogenesis, it is highly dependent on the variables that influence the 
outcome of a GTT, including glucose-stimulated insulin secretion (GSIS) and 
insulin sensitivity. It is thus important to analyze results from a PTT in light of 
data obtained from GSIS and ITT. Metabolic tests such as GTT and PTT mimic 
the conditions of a physiological meal intake. From our current study, glucose 
intolerance GSTP-null mice cannot be attributed solely to increased 
gluconeogenesis in vivo due to the observed defect in insulin secretion. Our 
finding of the decreased glucose-stimulated insulin levels adds a layer of 
complexity to the glucose metabolic phenotype and reinforces that the biologic 
function of GSTP in pancreatopathy and insulin secretion needs to be 
investigated further. In this regard, ex vivo studies of GSIS with isolated 
pancreatic islets are warranted. It is not known whether HFD decreases 
pancreatic GSTP function in WT mice or if GSTP deletion activates JNK in the 
pancreas. Pancreatic JNK activation could explain the decreased GSIS in GSTP-
null mice to contribute to the overall systemic phenotype. Ex vivo studies could 
test whether JNK inhibitor improves decreased GSIS in GSTP-null mice. 
Through this work, we have delineated a direct involvement of GSTP in 
hepatic glucose output and GSIS in mice; future genome-wide association 
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studies in diverse population groups may reveal whether GSTP is indeed a type 
2 diabetes candidate gene to further corroborate our present animal studies.  
In summary, this thesis continues the research efforts of our group to 
elucidate the link between detoxification mechanisms (GSTP), aldehydes and 
metabolic disease. Our general goal envisions identifying novel factors that 
govern interindividual susceptibility to obesity and diabetes. T2D is characterized 
by defects in both insulin sensitivity and insulin secretion that result in glucose 
intolerance, increased gluconeogenesis and hyperglycemia with severe 
consequences [154]. The genetic and environmental factors that promote 
inappropriate homeostatic control in diabetes remain inadequately understood. 
Given its role in cellular detoxification and stress kinase regulation, the redox 
sensor GSTP is unquestionably capable of influencing glucose homeostasis, 
probably through acrolein generation and adduction of critical proteins, but 
perhaps more importantly through JNK activation. This project adds to our 
knowledge of the possible pathways by which GSTP may affect glucose 
regulation. GSTP is highly polymorphic in humans. Further investments in 
understanding diet-induced GST dysregulation in human obesity, NAFLD and 
diabetes could have potentially important consequences for addressing inter-
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